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Bidirectional interactions between the immune and the nervous systems are of consider-
able interest both for deciphering their functioning and for designing novel therapeutic
strategies. The past decade has brought a burst of insights into the molecular mech-
anisms involved in neuroimmune communications mediated by dopamine. Studies of
dendritic cells (DCs) revealed that they express the whole machinery to synthesize and
store dopamine, which may act in an autocrine manner to stimulate dopamine receptors
(DARs). Depending on specific DARs stimulated on DCs and T cells, dopamine may differ-
entially favor CD4+ T cell differentiation into Th1 or Th17 inflammatory cells. Regulatory T
cells can also release high amounts of dopamine that acts in an autocrine DAR-mediated
manner to inhibit their suppressive activity. These dopaminergic regulations could repre-
sent a driving force during autoimmunity. Indeed, dopamine levels are altered in the brain
of mouse models of multiple sclerosis (MS) and lupus, and in inflamed tissues of patients
with inflammatory bowel diseases or rheumatoid arthritis (RA). The distorted expression
of DARs in peripheral lymphocytes of lupus and MS patients also supports the importance
of dopaminergic regulations in autoimmunity. Moreover, dopamine analogs had beneficial
therapeutic effects in animal models, and in patients with lupus or RA. We propose models
that may underlie key roles of dopamine and its receptors in autoimmune diseases.
Keywords: dendritic cell, regulatoryT cell,Th17, Crohn’s disease, multiple sclerosis, ulcerative colitis, systemic lupus
erythematosus, rheumatoid arthritis
Regulation of the immune system’s activities by other organs
occurs primarily through interactions with receptors expressed on
immune cells. Over the last years, studies of the neuroendocrine
and immune systems have indicated that neuropeptides, neuro-
transmitters, hormones, and cytokines, as well as their respec-
tive receptors, can be used as common mediators in a neuro-
endocrine–immune network, allowing the body to mount proper
responses to changes of the internal environment and external
insults (1). Interactions between the nervous and immune systems
occur through the hypothalamic–pituitary axis and through sym-
pathetic/parasympathetic innervations of primary and secondary
lymphoid organs. Remarkably, several neurotransmitter receptors,
including cholinergic receptors are expressed by human peripheral
blood lymphocytes (2). Among the critical transmitters involved in
neuroimmunolgical connections are catecholamines produced by
sympatho-adrenergic termini, which can release both dopamine
and/or norepinephrine.
Several studies have shown that immune system cells can be reg-
ulated by dopamine acting on immune cells expressing dopamine
receptors (DARs) present on the surface of T cells, dendritic cells
(DCs), B cells, NK cells, neutrophils, eosinophils, and monocytes
(3, 4). The presence of these receptors on immune cells suggests
that dopamine plays a physiological role in the regulation of the
immune response and that its deregulation could be involved
in the development of autoimmunity and, even, cancer (4, 5).
Furthermore, it implies that different physiological or pathological
processes in the nervous system could be involved in the regulation
of immune response. On the other hand, several studies show that
certain immune cells can synthesize and store dopamine in intra-
cellular vesicles and, upon specific stimuli, release it (6), suggesting
that dopamine operates as a bidirectional mediator between ner-
vous cells and immune cells. Here, we discuss the involvement
of the dopaminergic system in the pathogenesis of autoimmune
diseases.
NEUROIMMUNE INTERACTIONS IN CENTRAL NERVOUS
SYSTEM HOMEOSTASIS
Immune cells can be exposed to dopamine from several sources.
Plasma dopamine levels, which fluctuate depending on autonomic
nervous system activity and which are altered in various diseases,
are probably the primary source of dopamine available to immune
cells present in the blood stream (6). In this regard,chromaffin cells
in suprarenal glands may be the main source of plasma dopamine
when stimulated by the autonomic nervous system (7). Another
peripheral source of dopamine is the gut (8). Gastrointestinal
(GI) dopamine is produced by aromatic amino acid decarboxylase
(AADC) expressed in epithelial cells in the gut lumen and lumi-
nal l-DOPA (9). There are three additional sources of dopamine:
immune cells synthesizing and releasing dopamine, the peripheral
nervous system (PNS), and the central nervous system (CNS).
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The CNS parenchyma and cerebrospinal fluid (CSF) can be
important sources of dopamine for immune cells. Entrance of
immune system cells in the CNS parenchyma is restricted primar-
ily by the brain–blood barrier (BBB) that surrounds parenchymal
venules. The BBB is comprised of a first layer of endothelial cells
interconnected by tight junctions, which are surrounded by a
basement membrane, and an outer layer constituted by astroglial
endfeet (10). Under physiological conditions, no immune cells are
found in the CNS parenchyma. However, some immune cells may
infiltrate into the CSF, which is produced by choroid plexus epithe-
lia and flows into the subarachnoid space. Importantly, the CSF
drains into cervical lymph nodes, enabling peripheral immune
cells to recognize and respond to CNS antigens in the absence or
presence of inflammation (11, 12). Accordingly, the subarachnoid
space and choroid plexus of healthy mice contain substantial num-
bers of T cells and are heavily populated by myeloid cells, including
DCs (13). Importantly, under normal conditions, immune cells
found in the subarachnoid space are involved in surveillance of
the CNS. When activated by environmental/psychological stim-
uli, they can regulate nervous system processes, such as memory
consolidation, hippocampal long-term potentiation (LTP), neuro-
genesis, and psychological stress (14). In this regard, recent studies
have demonstrated that spatial memory and learning in healthy
animals are regulated by the presence of CD4+ T cells in the sub-
arachnoid space (15, 16). Whereas recombination-activating gene
2 (RAG2) knockout mice (RAG2KO), devoid of mature T cells
and B cells, show impaired performance in Morris-water maze
(MWM) tasks, µMT mice (deficient in B cells) display normal
learning and spatial memory, indicating that T cells, but not B
cells, are required to acquire memory (16). Moreover, class II
MHC-deficient mice, which are deficient in CD4+ T cells, but
whose CD8+ T cell compartment remains functionally intact, dis-
play significant impairment in MWM tasks (16). Along the same
lines, RAG1KO mice, which are, like RAG2KO mice, deficient in T
and B cells, improve their learning capability in MWM tasks upon
transfer of wild-type (WT) CD4+ T cells (16), further indicating
the important contribution of the CD4+ T cell compartment to
the acquisition of spatial memory. Importantly, pharmacological
interventions of WT mice with drugs that avoid entrance of T
cells into the meningeal compartment, such as FTY720 or anti-
VLA4 antibody, impair acquisition of spatial memory (15). In
particular, IL-4-producing T cells accumulate in the subarach-
noid space during cognitive tasks. In turn, IL-4 produced by Th2
cells stimulates hippocampal astrocytes to produce and release
brain-derived-neurotrophic-factor (BDNF) and probably other as
yet unidentified factors, which act subsequently on hippocampal
neurons, favoring spatial memory and learning (15). Such studies
demonstrated an impaired learning in mice lacking CD4+ T cells
or in mice bearing IL-4-deficient CD4+ T cells. In both cases, nor-
mal learning is recovered when WT CD4+ T cells were transferred,
thus linking immune activity to steady-state cognitive functions.
More recently, it has been shown that transfer of monoclonal trans-
genic CD4+ T cells bearing T cell receptors (TCRs) specific for
CNS antigens into RAG1KO mice, but not CD4+ T cells bearing
an ovalbumin-specific TCR, leads to improvement of the animal’s
capacity to acquire normal learning and spatial memory (16, 17).
Similar to the contribution of CD4+ T cells to acquisition of spatial
memory, there is growing evidence indicating that immunity to
self-antigens contributes to psychological stress resiliense (18).
Thus, the evidence suggests that T cells recognizing self-antigens
from the CNS are necessary to CNS homeostasis. The importance
of T cells in cognitive functions is also supported by observations
made during aging, HIV infection, and chemotherapy, conditions
associated with decreased or impaired T cell functions, and cogni-
tive impairments (14, 17). Potential dopaminergic regulation of T
cells and myeloid cells in the meningeal compartment remains to
be explored.
IMMUNE REACTIONS DURING NEUROINFLAMMATION AND
NEURODEGENERATION
As noted above, neuroimmune interactions in the CNS take place
in steady-state conditions. Additionally, the presence of infiltrat-
ing immune cells in the CNS parenchyma has been detected in
most neurodegenerative diseases studied (19). In a pathological
scenario involving the CNS, such as neurodegeneration or imbal-
ance of glial homeostasis, initial neuroinflammatory processes
induce brain endothelial cells to express a specialized pattern
of adhesion molecules on the cell surface. Adhesion molecules
induced by inflammatory processes subsequently allow activated
T cells to adhere to vessel walls and to be recruited into the CNS
parenchyma. Presumably, T cells that infiltrate the CNS have pre-
viously been activated in the periphery, in cervical lymph nodes
(12, 16). Once in the CNS parenchyma, infiltrating T cells can con-
tribute to regulate the neurodegenerative process by the secretion
of different cytokines and the recruitment of innate immune cells.
Additionally, molecules derived from immune cells can act over
glial cells, modulating microglia phenotype and function, includ-
ing M1-like microglia, which mediates neurotoxicity, and M2-like
microglia, which promotes neuroprotection (20). In this regard,
recent studies have shown that peripheral T cells infiltrate into
the brain parenchyma at the site of neuronal injury in Parkinson’s
disease, where they play a fundamental role in neurodegeneration
(21–23). This T cell-mediated immune response contributes sig-
nificantly to the destruction of dopaminergic neurons, through
a CD4+ T cell-dependent cytotoxic mechanism. These studies
support the involvement of pathogenic CD4+ T cell populations
in the acquisition of an M1-like pro-inflammatory phenotype by
microglia characterized by the secretion of inflammatory factors,
such as TNF-α, IL-1β, and superoxide (20). Importantly,dopamine
receptor D3 (DAR3) expressed in CD4+ T cells is fundamental for
promoting destruction of dopaminergic neurons in the substantia
nigra in a mouse model of Parkinson’s disease (22). As a result,
DAR3-deficient (DAR3KO) mice are resistant to 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinson’s
disease. However, when WT CD4+ T cells were transferred into
DAR3KO mice, they acquired the capability to respond to MPTP-
induced neurodegeneration. On the other hand, RAG1KO mice,
which are resistant to MPTP-induced Parkinson’s disease, acquire
the capacity to respond to MPTP-induced neurodegeneration
when WT, but not DAR3KO, CD4+ T cells were transferred (22).
Furthermore, CD4+ T cells that infiltrate in the substantia nigra
during MPTP-induced Parkinson’s disease produced high levels
of IFN-γ and TNF-α, two cytokines that act synergistically in
microglia to promote the inflammatory M1-like phenotype (24).
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Thus, these findings point toward an important role of CNS-
derived dopamine in the regulation of T cell-mediated immu-
nity during neuroinflammation. Conversely, other T cell subsets,
i.e., regulatory T cells (Tregs) and Th2 cells, could contribute to
microglial acquisition of an M2-like anti-inflammatory pheno-
type, releasing neurotrophic factors, such as IGF-1, and promoting
neuronal protection (20, 23). In contrast to the role of CNS-
infiltrating T cells in Parkinson’s disease, studies carried out in
amyotrophic lateral sclerosis (ALS) have shown that absence of
T cells accelerates motoneuron disease while adoptive transfer
of T cells ameliorates disease severity (19). These results could
be explained by the contribution of T cells to the acquisition of
M2-like phenotype by microglia. Consistently, both Treg numbers
and FoxP3 protein expression were reduced in rapidly progressing
ALS patients and inversely correlated with progression (25). Inter-
estingly, expression of two Th2 molecular markers, GATA3 and
IL-4, was also decreased in peripheral T cells in rapidly progress-
ing patients and inversely correlated with progression rates (25).
Thus, an imbalance of neuroimmune interactions may constitute
an important component of the pathogenic mechanisms involved
in neurodegenerative disorders regulating the onset and progres-
sion, and dopamine may be a key mediator in these neuroimmune
interactions, such as demonstrated for Parkinson’s disease (22).
SYMPATHETIC NERVOUS SYSTEM-MEDIATED REGULATION
OF IMMUNITY
An important peripheral source of dopamine and other neuro-
transmitters is the innervation of primary and secondary organs
by the sympathetic nervous system (SNS). For example, dopamin-
ergic terminals have been detected in thymus, spleen, and lymph
nodes where the SNS seems to play a role in regulation of T
cell-mediated responses (26). The relevance of SNS-mediated reg-
ulation of immunity has been demonstrated by several studies that
were mainly carried out in mice that received 6-hydroxydopamine,
a neurotoxic drug that selectively ablates noradrenergic and
dopaminergic neurons. This latter molecule is captured specif-
ically through dopamine transporters (DAT) or norepinephrine
transporters (NET), and, when administered systemically, it can-
not cross the BBB. As a result, 6-hydroxydopamine depletes the
SNS without affecting the CNS. NE is the main neurotrans-
mitter released by the SNS and, thereby, this is probably the
main neurotransmitter responsible for SNS-mediated regulation
of immunity, although dopamine has also been involved in SNS-
mediated regulation of T cell responses. The evidence points to
a dual role of the SNS in T cell responses. First, the SNS inhibits
TGF-β production in the spleen and lymph nodes, thereby atten-
uating generation and function of Tregs. Thus, sympathectomy
attenuates disease severity of mice with collagen-induced arthritis
(CIA) or experimental autoimmune encephalomyelitis (EAE) as
compared with animals bearing intact SNS (27, 28). Second, by
stimulating β2-adrenergic receptors, the SNS attenuates immuno-
genicity of antigen-presenting cells (APCs) in secondary lymphoid
organs, decreasing the potency of both Th1 response and CD8+
T cell-mediated cytotoxicity. This attenuation seems to alter the
immune response during infection with influenza virus (29) or Lis-
teria monocytogenes (30). In both cases, sympathectomized mice
mount a stronger antiviral or antibacterial response than control
mice (29, 30). Thus, the SNS displays a dual role, potentiating
autoimmune responses and attenuating antiviral and antibacterial
responses. This dual function could be explained by a mechanism
in which SNS-mediated attenuation of Th1 responses concomi-
tantly favors Th17 responses. Another mechanism could involve
dopamine. Indeed, SNS neurons express the enzyme dopamine-
β-hydroxylase (DβH), which catalyzes the synthesis of NE from
dopamine, a neurotransmitter normally present in low amounts in
mouse SNS neurons. However, in DβH-deficient mice (DβHKO),
noradrenergic neurons become exclusively dopaminergic, and
the mice develop an attenuated antibacterial response against
L. monocytogenes (31). Thus, exacerbated dopamine signaling by
the SNS results in a decreased Th1 response.
IMMUNE CELLS AS A SOURCE OF DOPAMINE
An increasing number of studies revealed that cells involved in
both adaptive and innate immune responses, such as DCs, T cells,
B cells, and macrophages are capable of synthesizing neurotrans-
mitters (32). Under specific stimuli, these cells may release neu-
rotransmitters into the extracellular compartment, thus enabling
communications with other different cell types. These interactions
not only suggest that neurotransmitters can mediate communica-
tion between immune cells, but also that these molecules may
be involved in a bidirectional cross-talk between the immune
and the nervous system. With regard to dopamine, early stud-
ies showed that in vitro activation of human peripheral blood
mononuclear cells (PBMCs) with mitogens induces production
of intracellular dopamine and other catecholamines, probably
involving both T and B lymphocytes (33, 34). Currently, sev-
eral studies performed in human and mouse cells indicate that
DCs and Tregs constitute dopamine sources. DCs express tyro-
sine hydroxylase (TH), which catalyzes the first step required for
dopamine biosynthesis (Figure 1). However, these cells do not
express dopamine-β-hydroxylase, the enzyme required to metab-
olize dopamine and to transform it into epinephrine and NE
(35). In addition, DCs do not express DAT, required to take up
dopamine from the extracellular compartment. Thus, DCs syn-
thesize dopamine, but not other catecholamines, and they cannot
capture dopamine from the extracellular space. These cells also
express enzymes necessary to degrade dopamine in the cytoplasm:
monoaminooxidases A and B (MAO-A, MAO-B) and vesicular
monoamine transporter 2 (VMAT-2) required to store dopamine
in vesicular compartments. In addition, human DCs contain intra-
cellular dopamine, which is released upon antigen presentation
to T cells (36). On the other hand, human Tregs constitutively
express TH and contain substantial amounts of dopamine and
other catecholamines, while effector T cells only contain trace
amounts (37). Tregs also express VMAT-1 and VMAT-2, which
allows them to accumulate catecholamines in vesicular stores (37).
Interestingly, physiologically relevant amounts of dopamine are
released by Tregs when stimulated by reserpine, a natural drug
used to deplete monoamines (37). Addressing the physiological
stimuli evoking release of intracellular catecholamines from lym-
phocytes, in vitro treatment of mitogen-stimulated PBMCs with
IFN-β induces a stronger production of catecholamines and the
release of these mediators into the culture supernatant (38), thus
suggesting that IFN-β is an endogenous stimulus for secretion of
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FIGURE 1 | Dopamine produced by dendritic cells and amplification
of inflammation. Dendritic cells (DCs) express tyrosine hydroxylase
(TH), which catalyzes the first step required for dopamine (DA)
biosynthesis. However, since these cells do not express dopamine
β-hydroxylase, the enzyme required to metabolize DA and to transform
it into epinephrine and norepinephrine, they accumulate DA. DCs also
express vesicular monoamine transporters 1 and 2 (VMAT) required to
store DA in vesicular compartments. In response to antigen
presentation or to LPS stimulation, DCs release DA from intracellular
stores, which can modulate both DC physiology in an autocrine manner
and CD4+ T cell responses in a paracrine fashion (not depicted). At
certain concentrations, DC-derived DA interacts with DAR5 expressed
by DCs, which promotes IL-23 production in response to LPS, and,
thereby, enhances Th17 responses.
catecholamines from lymphocytes. Other immune cells have been
described to store dopamine in intracellular compartments. In this
regard, stimulation of B cells with mitogens induces up-regulation
of TH mRNA expression followed by production of intracel-
lular dopamine and other catecholamines by a PKC-dependent
mechanism (34). In addition, it has been shown that intracel-
lular vesicles containing dopamine in B cells can be released
by Ca2+-dependent mechanisms (39). Similarly, other studies
suggest the existence of dopamine-containing vesicles in mono-
cytes/macrophages (39, 40). Neutrophils and mast cells have been
also suggested to contain dopamine (39, 41). Further experimental
work is necessary to understand the relevance of these immune
cells as sources of dopamine in neuroimmune interactions and in
leukocyte–leukocyte communications.
DOPAMINE RECEPTOR EXPRESSION IN THE IMMUNE
SYSTEM
Dopamine receptors have been found not only in cells of the innate
immune response such as DCs, NK cells, macrophages/monocytes,
and granulocytes (35), but also in cells of the adaptive immune
response, such as B cells, CD8+ T cells, and CD4+ T cells (36, 42–
45). DARs expression has also been described in murine T cells (45,
46). Pharmacological evidence obtained from studies performed
with human T cells has suggested that, among the five known
DARs (DAR1–DAR5), both type I (DAR1 and DAR5) and type II
(DAR2, DAR3, and DAR4) receptors contribute to the regulation
of T cell functions. It has been suggested that stimulation of type I
DARs expressed on human naive CD4+ T cells potentiates the pro-
duction of Th2 cytokines (36). Other investigators have suggested
that stimulation of type I DARs on human Tregs can decrease IL-
10 and TGF-β production and their suppressive activity (37), and
that DAR4 stimulation on human T cells promotes quiescence
(44). On the other hand, there is evidence that stimulation of
DAR2 and DAR3 in normal human resting T cells favors produc-
tion of IL-10 and TNF-α, respectively (42), and that stimulation
of DAR3 in resting T cells favors activation of β1-integrins and
adhesion to fibronectin, two critical events required for cell migra-
tion (45). Importantly, DAR3 stimulation in human activated
CD4+ T cells decreases IL-4 and IL-10 synthesis and potentiates
IFN-γ production, a key cytokine for Th1 cells; and pharmaco-
logic DAR3 stimulation in human T cells potentiates expression
of surface activation markers (47). In contrast, other studies indi-
cated that dopamine, at concentrations that selectively stimulate
DAR3, inhibits human T cell proliferation (43, 48). In addition to
the different stimulatory effects of DARs in T cell physiology, it
is important to consider that each DAR displays different affini-
ties for dopamine: DAR3>DAR5>DAR4>DAR2>DAR1 [Ki
(nM)= 27, 228, 450, 1705, 2340, respectively] (49–51). Thus, low
levels of dopamine, e.g., 50 nM, would stimulate mainly DAR3 in
T cells, favoring Th1-like responses and T cell migration, whereas
moderate dopamine levels, e.g., 300 nM, would stimulate DAR5
as well, inhibiting T cell function. It is likely that, by stimulating
multiple DARs, higher dopamine levels promote complex effects
in T cells, probably inhibiting T cell-mediated immunity (4).
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Regarding DCs, DAR1 and DAR5 are expressed at higher levels
on the cell surface, whereas DAR3 and DAR2 are poorly repre-
sented on DCs (35). It has recently been demonstrated that stimu-
lation of DAR5 on DCs strongly potentiates production of IL-23, a
regulatory cytokine that favors polarization of naive CD4+ T cells
toward the inflammatory Th17 phenotype (Figure 2). Specifically,
stimulation of DAR5 on DCs potentiates Th17 responses in vitro
and in vivo (35). Other pharmacological evidence indicates that
selective stimulation of DAR2/DAR3 or selective inhibition of
DAR1/DAR5 on DCs favors polarization of CD4+ T cell responses
toward Th1, but impairs the Th17 fate (52). Thus, depending on
the concentration of dopamine, the specific DARs expressed and
the type of immune cell bearing DARs, this neurotransmitter may
induce different effects in the immune response.
Emerging evidence has shown association of some autoim-
mune disorders with abnormal dopamine levels and deregula-
tion of dopaminergic components expressed in immune cells.
For example, dopamine levels are altered in the brain of mouse
models of multiple sclerosis (MS) and systemic lupus erythemato-
sus (SLE), and in inflamed tissues of patients with inflammatory
bowel diseases (IBDs) or rheumatoid arthritis (RA). The distorted
expression of DARs in peripheral lymphocytes of SLE and MS
patients supports the importance of dopaminergic regulations in
autoimmunity. Here, we critically discuss the role of dopaminer-
gic regulation of the immune response and its implications with
regard to autoimmune disorders.
CELL SUBSETS INVOLVED IN MULTIPLE SCLEROSIS
PATHOGENESIS
Multiple sclerosis is a chronic demyelinating disease resulting from
an autoimmune response against constituents of the CNS. With
approximately 2.4 million individuals affected world wide, the dis-
ease is characterized by CD4+ T cell-mediated progressive loss
of neurological function due to the destruction of axonal myelin
sheath in several areas of the brain and spinal cord. Loss of myelin is
manifested in clinical symptoms such as paralysis, muscle spasms,
optic neuritis, and neuropathic pain (53). Pathological features of
MS lesions include BBB permeability, myelin sheath destruction,
axonal damage, glial scar formation, and presence of lympho-
cytes and inflammatory cells infiltrated into the CNS (54). Despite
intense investigation, the etiology of MS is still unclear; but genetic
and environmental factors have been suggested to be important in
disease development.
Several cell types are present in the CSF and microvasculature.
An increased number of DCs with an exacerbated state of mat-
uration have been found in the CSF and lesions of patients with
MS (55). It is thought that, in healthy individuals, CNS-resident
DCs play a role in the induction of peripheral tolerance to CNS-
derived self-constituents, including myelin. However, due to the
abnormal mature phenotype of DCs and their proximity with
infiltrated T cells in the CNS of MS patients, DCs could play an
important role in presenting self-antigens and in re-stimulating
self-reactive T cells infiltrated into the CNS. In addition, peripheral
FIGURE 2 | Altered CD4+ T cell programing by different dopamine
concentrations. Effector CD4+ T cells lack the ability to synthesize DA,
but may be exposed to DA produced by DCs, Tregs, or by other sources
(not depicted). At intermediate DA concentrations, stimulation of DAR4
expressed by effector CD4+ T cells leads to cell quiescence by inducing
expression of KLF2, a transcription factor that regulates T cell quiescence.
At lower DA concentrations, stimulation of DAR3 expressed on DCs
results, by means of an undefined mechanism, in heightened Th1
responses along with a reduction in Th17 immunity and a reduction of
Th2-related cytokines.
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blood DCs from MS patients produce increased amounts of IL-6,
IFN-γ, and TNF-α (56). Importantly, these DCs are capable of
promoting differentiation of CD4+ T cells toward the inflamma-
tory Th17 phenotype (57). These observations support the notion
that abnormal function of DCs from MS patients can promote an
inappropriate functional phenotype in self-reactive T cells, con-
tributing to the development of autoimmunity. In addition to
CD4+ T cells, CD8+ T cells have also been described as an impor-
tant cell subset in the disease (58). In fact, the frequency of CD8+
T cells is greater than that of CD4+ T cells in inflamed MS plaques,
and CD8+ T cells show oligoclonal expansion in plaques, CSF, and
blood, suggesting an important role of these cells in MS. In this
regard, a group of studies performed in mice and in humanized
mice showed participation of CD8+ T cells in EAE (58). B cells are
also important by promoting the autoimmune response involved
in MS; and it has been suggested that IL-6-producing B cells are
the pathogenic cell subset that promotes functions of self-reactive
T cells (59). Importantly, treatment with rituximab, an anti-CD20
antibody that alleviates symptoms of MS patients (60), induces
preferential depletion of IL-6-producing B cells (59).
DOPAMINERGIC REGULATION IN MULTIPLE SCLEROSIS
Experimental autoimmune encephalomyelitis is a widely used
mouse model of MS. It can be induced by injection of a peptide
derived from the myelin-oligodendrocyte glycoprotein (MOG),
MOG35–55 (pMOG), emulsified with adjuvant (35). Adminis-
tration of myelin-derived antigens in an immunogenic context
promotes activation of self-reactive T cells specific for myelin
antigens, which mediate myelin destruction characterized by focal
areas of demyelination along the CNS, with axonal loss that results
in ascending paralysis, affecting first the tail and then the hind
limbs. During EAE onset and at the peak of disease manifestations,
there is an important increase of dopamine levels in the striatum
nucleus (61). Interestingly, levels of IL-1β and TNF-α mRNAs
increase in the striatum nucleus with the same kinetics followed
by dopamine (61). On the other hand, there is decreased expres-
sion of DAR5 in PBMCs obtained from untreated MS patients
when compared with PBMCs obtained from healthy donors (62).
Furthermore, when patients are treated with IFN-β, there is a pro-
gressive increase of the expression of DAR5 in PBMCs during
the treatment period (63). It is possible that decreased expression
of DAR5 on PBMCs could be a pathogenic factor favoring dis-
ease manifestations. Alternatively, DAR5 expressed on these cells
could represent a detrimental factor in MS; and, somehow, a com-
pensatory down-regulation of this receptor could be promoted
in MS patients. Moreover, altered production of catecholamines
by PBMCs, which is modulated through type I DARs (34), seems
also to occur in PBMCs from MS patients (33). Importantly, IFN-
β, which has been shown to be therapeutic for the treatment of
MS, promotes a progressive increase of TH expression with a con-
sequent increase of catecholamines production in PBMCs (63).
It is noteworthy that IFN-β is capable to induce release of cate-
cholamines from PBMCs in vitro (38); however, the physiological
relevance of this IFN-β function remains unclear. These results
suggest a relationship between expression of components of the
dopaminergic system in immune cells and MS development (see
Table 1).
Of late, it was demonstrated that DCs express the whole
machinery to synthesize and store dopamine (35). The dopamine
released from DCs subsequently acts in an autocrine manner to
stimulate DAR5 expressed on DCs,promoting a potent production
of IL-23 by DCs, thus conferring these cells with the ability to favor
polarization of naïve CD4+ T cells toward the inflammatory Th17
phenotype (35). Since IL-23 can also stimulate γδT cell functions
(64) and GM-CSF-producing CD4+ T cells (65), two cell subpopu-
lations involved in EAE pathogenesis, the DAR5 expressed on DCs
could play a role in EAE by regulating the activity of various target
T cell populations. This autocrine loop mechanism mediated by
dopamine and stimulation of DAR5 on DCs could represent a dri-
ving force in the autoimmune response during EAE development.
Supporting this notion, DAR5KO mice manifest EAE with signifi-
cantly lower severity than WT mice (35). In addition, prophylactic
transfer of DAR5KO DCs loaded with pMOG into WT recipi-
ent mice significantly reduces EAE severity when compared with
WT recipient mice transferred with pMOG-loaded WT DCs (35).
In the same direction, another study has shown that systemic
administration of a selective antagonist for type I DARs decreased
significantly EAE severity (52). Furthermore, attenuated disease
severity correlates with decreased numbers of Th17 and IFN-γ+
IL-17+ CD4+ T cells infiltrated into the CNS of WT mice trans-
ferred with DAR5KO DCs when compared with those transferred
with WT DCs. Conversely, there are no differences in the frequen-
cies of Tregs or Th1 cells infiltrated into the CNS when compared to
WT mice transferred with DAR5KO DCs versus those transferred
with WT DCs. However, the participation of γδT cells, GM-CSF-
producing CD4+ T cell, and CD8+ Tregs has not been explored.
Regarding dopaminergic regulation of T cells, the physio-
logic stimulus that induces dopamine release from Tregs remains
unknown. Yet, when treated with reserpine, a drug used to deplete
dopamine from dopaminergic cells, Tregs release high amounts
of dopamine, which acts in an autocrine manner to inhibit their
suppressive activity. Pharmacological evidence suggests that this
inhibition of Treg suppressive activity is mediated through type I
DARs, including DAR1 and/or DAR5 (37). Accordingly, a recent
study that analyzed the suppressive function and expression of
the dopaminergic machinery in Tregs obtained from MS patients
or from healthy controls found that DAR5, as well as TH, were
up-regulated in Tregs from untreated MS patients when com-
pared with those from healthy controls; however, both TH and
DAR5 were down-regulated when Tregs were obtained from IFN-
β-treated MS patients (66). Whereas the suppressive function
was partially or completely inhibited by dopamine when Tregs
were obtained from healthy controls or untreated MS patients,
respectively, dopamine-mediated inhibition of Treg function was
abolished when Tregs were obtained from IFN-β-treated MS
patients (66). Interestingly, DAR3 expression in Tregs was unal-
tered in untreated MS patients, but significantly decreased in
IFN-β-treated MS patients when compared with healthy controls
(66). Importantly, inhibition of Treg function could be achieved
by 1µM dopamine (66). Considering the affinity of dopamine for
DARs expressed on human Tregs (DAR1, DAR3, and DAR5) and
the pharmacological evidence obtained using dopamine analogs
in these cells (37), the results suggest that the inhibitory effect
exerted on Treg suppressive functions is mediated by DAR5, rather
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Table 1 | Observations linking the dopaminergic system with the development and progression of autoimmune disease.
Disease Experimental mouse models Reference Patients Reference
Multiple sclerosis Increased dopamine levels in the striatum
nucleus during EAE peak
(61) Decreased expression of DAR5 in PBMCs
obtained from untreated MS patients
compared with healthy donors
(62)
Administration of the DAR1-like antagonist
SCH-23390 prevents the development of
EAE
(52) Increased expression of DAR5 and TH,
along with elevated catecholamine
content in PBMCs of MS patients treated
with IFN-β
(63)
Stimulation of DAR5 on DCs promotes
Th17-driven EAE
(35) Treatment of MS patients with IFN-β
reduces high levels of DAR5 and TH
expressed on Tregs and abolishes
dopamine-mediated inhibition of
suppressive activity of Tregs
(66)
Inflammatory bowel
diseases
TNBS-induced colitis is associated with
reduced tissue levels of dopamine
(96) Inflamed gut mucosa from CD and UC
patients shows a marked reduction of
dopamine content
(95)
6-Hydroxydopamine-induced sympathectomy
increases gut inflammation in chronically
DSS-treated and IL-10-deficient mice
(97) CD patients have reduced numbers of
sympathetic fibers interacting with the
intestinal wall
(97)
Dopamine acts via DAR2 to suppress both
increased motility and ulcer development
induced by chemical insult
(102) A genetic polymorphism of DAR2 gene,
which results in reduced receptor
expression, has been reported as a risk
factor to develop refractory CD
(103)
Rheumatoid arthritis Treatment with the selective DAR1-like
antagonist SCH-23390 suppresses
collagen-induced arthritis severity, probably
due to inhibition of macrophage
differentiation into osteoclasts
(108) Dopamine is significantly increased in the
synovial tissue of RA patients
(107)
Selective DAR2-like receptor antagonist
haloperidol significantly exacerbated cartilage
destruction, whereas DAR1-like receptor
antagonist SCH-23390 strongly suppresses
RA development
(107) Administration of bromocriptine, a DAR2/3
agonist, suppresses immune parameters
and reduces RA disease activity
(112)
Adoptive transfer of TH+ cells generated
from mesenchymal stem cells reduces
collagen-induced arthritis severity
(111) Treatment of active RA with cabergoline, a
DAR2/3 agonist, significantly reduces
disease activity
(113)
Dopamine-producing TH+ leukocytes with
anti-inflammatory properties are found in
synovial tissue of RA patients, but not in
healthy controls
(110)
Systemic lupus
erythematosus
Lupus-prone MRL-lpr mice have impaired
coordination and neurological deficits, with
imbalanced dopamine function and
neurodegeneration in dopamine-rich brain
regions
(120) Autoantibodies targeting dopaminergic
neurons are associated with rapidly
progressing Parkinsonian
symptomatology in a SLE patient
(119)
Brains of MRL-lpr mice show elevated levels
of dopamine and increased sensitivity to the
DAR2/3 receptor agonist quinpirole,
suggesting a neurotoxic role for dopamine
(122) SLE patients show reduced expression of
DAR2 and increased DAR4 levels on
PBMC-derived T cells compared to
healthy individuals
(123)
(Continued)
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Table 1 | Continued
Disease Experimental mouse models Reference Patients Reference
Chronic administration of the selective
DAR2/3 agonist quinpirole induces
self-injurious behavior in lupic mice
(121) Treatment with bromocriptine, a DAR2/3
agonist, is beneficial in SLE patients with
mild to moderately active disease, leading
to decreased serum immunoglobulin and
anti-DNA antibody levels
(112)
Bromocriptine, a DAR2/3 agonist, slows the
course of SLE in (NZB×NZW) F1 mice and
is effective in treating established disease in
this model
(125)
Combined treatment with estrogen and
bromocriptine, a DAR2/3 agonist, prevents
development of a lupus-like syndrome in
BALB/c mice expressing a transgenic
anti-dsDNA antibody
(126)
DC, dendritic cell; CD, Crohn’s disease; EAE, experimental autoimmune encephalomyelitis; DAR, dopamine receptor; MS, multiple sclerosis;TH, tyrosine hydroxylase;
UC, ulcerative colitis.
FIGURE 3 | Contrasted effects of dopamine produced by
regulatoryT cells. Tregs constitutively express TH and contain
substantial amounts of DA. They also express VMAT-1 and VMAT-2,
which allows them to accumulate DA in vesicular stores. In response
to yet unknown physiological stimuli, Tregs release DA, which can
interact with DARs expressed on the Treg cell surface, but also with
DARs present on DCs and effector CD4+ T cells (not depicted).
Treg-derived DA interaction with DAR1/5 expressed by Tregs, reduces
the expression of IL-10 and TGF-β, and weakens the Treg’s suppressive
activity exerted over effector CD4+ T cells.
than DAR1. Thus, these results support the notion that DAR5
stimulation could be involved in inhibition of Treg suppressive
activity (Figure 3). On the other hand, because DAR5 expression
is altered in MS patients, these findings also suggest the involve-
ment of DAR5 expressed on Tregs in the physiopathology of MS
(see Table 1). Since CD8+ T cells and B cells are also involved in
MS pathogenesis, and because DARs are expressed in these cell
populations, further efforts are necessary to understand the role
of dopaminergic regulation of these cells in MS. Moreover, further
experimental work is necessary to provide an integrated view of
the role of dopaminergic regulation in the autoimmune response
during MS. Further understanding of the precise mechanisms
involving dopaminergic-mediated regulation of the immune sys-
tem and their alterations in MS could lead to development of drugs
useful for MS treatment.
MUCOSAL IMMUNE SYSTEM IN INFLAMMATORY BOWEL
DISEASES
Inflammatory bowel diseases form a group of chronic remittent
inflammatory affections of the GI tract, among which Crohn’s
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disease (CD) and ulcerative colitis (UC) are the most com-
mon. The overall IBD prevalence approximates 500–900 cases
per 100,000 individuals, and has shown a marked increase dur-
ing the last decades, mainly in westernized nations (67, 68). In
terms of clinical manifestations, both CD and UC share several
symptoms such as abdominal pain, anemia, weight loss, and diar-
rhea, but they also differ in a number of pathological features.
Lesions in CD may occur anywhere from the mouth to the anus,
with a preference for the ileum, while UC patients typically present
lesions restricted to the colon. UC involves mostly mucosal inflam-
mation, while CD is characterized by discontinuous transmural
inflammation. In addition, UC may evolve to toxic mega-colon or
predispose to colorectal cancer, while CD may progress into peri-
anal fistulas, abscesses, and strictures, which may lead to intestinal
obstructions (69). Evidence from IBD mouse models has asso-
ciated different CD4+ T helper lineages as the main drivers of
inflammation, linking CD development to Th1/Th17 responses,
and UC to Th2 responses (70). More recently, however, both gene
and protein expression studies have confirmed that inflamed sam-
ples from both UC and CD patients are dominated by Th1/Th17
markers with little or no signs of Th2 contribution, suggesting that
established inflammation in IBD is mainly driven by Th1/Th17
cell populations (71, 72). Treatment of these conditions relies on
classical anti-inflammatory and immunosuppressive drugs such as
mesalamine compounds, corticosteroids, and azathioprine. How-
ever, these agents are known to vary in their ability to control the
symptoms and to be toxic. Novel therapies rely on neutralizing
antibodies raised against inflammatory cytokines such as TNF-α
and the p40 subunit of IL-12 and IL-23, which are important in the
innate response that polarizes adaptive immunity and perpetuates
inflammation (69, 73).
Current understanding of IBD pathogenesis indicates that these
disorders are driven by an excessive immune response against
normal constituents of the mucosal microbiota in genetically pre-
disposed individuals. Specifically, intestinal microbiota is able to
modulate the mucosal immune response and seems to play a
key role in IBD pathology (74). Several observations suggest that
inflammation per se may cause dysbiosis, and severe inflamma-
tion might be associated with profound changes in the intestinal
microflora, acting as a perpetuating factor in IBD by increas-
ing the contribution of commensals with pathogenic tendencies
among the community (75). Additionally, the epithelial barrier
plays a crucial role in maintaining mucosal homeostasis as it
orchestrates the communication between the intestinal mucosa
and luminal contents, and as it establishes an appropriate sub-
strate for commensal microbiota. These various players enable the
mucosal immune system to continuously sample luminal contents
and to be able to decide between tolerating commensal microflora
and dietary antigens, or activating and responding to invading
pathogens. Through several mechanisms, sampled antigens are
transported to APCs, like DCs and macrophages. Several stud-
ies have regarded DCs and macrophages as inducers of intestinal
inflammation (76, 77). In contrast to DCs and macrophages,
NK cells attenuate intestinal inflammation induced by transfer
of IL-10-deficient CD4+ T cells into immunodeficient hosts by a
mechanism dependent on perforin (78).
Activation of innate immunity leads to recruitment and acti-
vation of several components of the adaptive immune response,
which mediate damage of intestinal tissues in IBDs and their
mouse models. Th1 cells were initially credited as inflammation
inducers in experimental colitis. Further studies drew attention
to the involvement of Th17 cells in IBDs. Thus, IL-17 expres-
sion is increased in both CD and UC, with a higher frequency
of IL-17-producing CD4+ T cells in colonic mucosa of CD
patients (79, 80). In addition, Tregs seem to play a crucial role
in maintaining intestinal homeostasis. These cells can suppress
inflammation induced by CD4+ CD45RBhi T cells in a T cell
transfer model of colitis (81); and one of the main suppres-
sive mechanisms relies on IL-10 secretion by these cells. Thus,
specific IL-10 deletion of Foxp3+ Tregs results in spontaneous
colitis, highlighting the fact that IL-10 produced by Tregs is instru-
mental in maintaining tolerance particularly at intestinal tissues
(82). In humans, CD4+CD25+Foxp3+ Treg cells are increased
in the inflamed lamina propria of CD and UC patients com-
pared to uninflamed mucosa and mucosa from healthy controls,
and they retain their ability to suppress CD4+CD25− T cells,
suggesting that Treg function is not altered during the course
of intestinal inflammation (83, 84). In accordance with these
data, T cells from IBD patients were found to be resistant to
suppressive molecules, such as TGF-β, resulting in excessive T
cell-mediated inflammation (85). Alterations in additional reg-
ulatory populations of T cells have been reported in IBDs, such
as CD8+ CD28− T cells, which are reduced or absent in the lam-
ina propria of IBD patients. Regulatory B cells have also been
associated with these diseases, as they are detected in inflamed
sites and can suppress the progression, but not the initiation
phase of colitis (86, 87). Finally, it is important to note that NKT
cells, which respond to phospho- or glycolipids rapidly produce
Th1-, Th2-, and Th17-associated cytokines, major drivers of UC
pathology (88).
DOPAMINE AND MUCOSAL IMMUNITY IN INFLAMMATORY
BOWEL DISEASES
Cells residing in the GI tract may encounter the neuromodula-
tor dopamine, which can be produced from different sources,
including the enteric nervous system, the intestinal epithelial
layer, and certain immune cells, as described above. The intes-
tine receives extrinsic signals from the CNS by means of sympa-
thetic and parasympathetic nerve fibers belonging to the auto-
nomic nervous system. While sympathetic fibers arise from the
corresponding spinal nerves, parasympathetic fibers derive from
the vagus nerve. Both vagal and spinal fibers connect within
the gut wall at different points, interacting with the “intrinsic”
enteric nervous system. The latter is organized in three lay-
ers, which include the myenteric plexus, located between the
circular and longitudinal muscle layers, the submucosal plexus,
localized at the submucosa, and the mucosal plexus, which con-
tains nerve endings in close proximity to immune and epithelial
cells. This system includes sensory neurons, interneurons, motor
neurons, and enteric glial cells, and secretes more than 30 dif-
ferent neurotransmitters, with most neurons expressing multiple
neurotransmitters (89).
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Dopamine is detectable in the intestine, but it remains unclear
if this neuromodulator comes from extrinsic or intrinsic inner-
vations (90). Several lines of evidence support the view that
dopamine is produced by intrinsic enteric neurons, since gas-
tric fibers are immunoreactive with dopamine, and because nerve
stimulation of the guinea pig stomach results in dopamine release
(91). Furthermore DAT immunoreactivity has been detected in
enteric nerves (92). In addition, the specific dopamine-derived
metabolite dihydroxyphenylacetic acid (DOPAC) has been found
in the mouse intestine, and treatment with 6-hydroxydopamine,
an agent that ablates neurons expressing DAT or NET, results in
depletion of enteric dopamine (90). Enteric dopamine has also
been reported in human myenteric neurons, which are depleted in
Parkinson’s disease patients (93). Additional studies have shown
that TH, dopamine, and DAT immunoreactivities colocalize in
subsets of neurons from mouse intestines, known to be resis-
tant to extrinsic denervation, thus strongly suggesting that enteric
dopaminergic neurons are intrinsic (94). On the other hand,
dopamine may be synthesized by epithelial cells of the intestinal
mucosa, which show high AADC activity and are exposed both to
circulating or luminal l-DOPA (9). Interestingly, inflamed mucosa
from CD and UC patients shows a marked reduction of dopamine
content (95), which may alter the activation or differentiation
status of DAR-expressing immune cells, such as inflammatory
T cells, Tregs, B cells, macrophages, NK cells, and DCs. Consis-
tently, 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis
has been associated with reduced tissue levels of dopamine and
no changes in AADC activity (96). The authors hypothesized that
the mechanism behind dopamine reduction under inflammatory
conditions might be explained by the reduced uptake of l-DOPA
by cultured epithelial cells upon IFN-γ treatment (96). However,
the in vitro model of intestinal epithelial cells is an over-simplified
system that lacks many cellular and molecular mediators. An alter-
native explanation comes from work showing that CD patients
have reduced numbers of sympathetic fibers interacting with the
intestinal wall, and that 6-hydroxydopamine-induced sympathec-
tomy increases the inflammation in chronically DSS-treated and
IL-10-deficient mice, strongly supporting an anti-inflammatory
role of sympathetic nerves in IBDs (97). As previously observed
for the cholinergic anti-inflammatory reflex, autonomic circuits
may relay signals with the use of different neurotransmitters, and,
in that way, a cholinergic pathway, i.e., the vagus nerve, may stim-
ulate NE release into the target tissue, i.e., the splenic nerve (98).
This could also be the case in the enteric nervous system, where
neurons from the enteric nervous system could respond to vagus
nerve stimulation by secreting locally relevant neuromodulators,
such as dopamine (99). Thus, the reduced sympathetic innerva-
tion observed in CD patients could account for reduced levels of
dopamine, also observed in mouse models of colitis.
As mentioned above, development of IBD results from an exces-
sive mucosal immune response in genetically predisposed individ-
uals, who may have alterations in one or various processes that
ensure mucosal homeostasis. For example, deregulated intestinal
motility may lead to lesion induction, and, eventually, to ulcer
development, which may predispose to inflammation. In this
context, dopamine or its agonists have been reported to act as pro-
tective agents in various rat ulcer models (100, 101). More recently,
it was shown that dopamine acts via DAR2 to suppress both
increased motility and ulcer development induced by chemical
insult (102). These findings suggest that, by controlling intestinal
motility, dopamine may reduce the propensity to develop ulcers
upon intestinal injury. In line with this notion, a genetic polymor-
phism of DAR2 gene, which results in a reduced receptor expres-
sion, has been reported as a risk factor to develop refractory CD
(103). Another study showed participation of dopamine acting via
DAR1 in smooth muscle inhibition of acute cold/restraint stress-
induced contraction in the distal colon of the rat (104). Moreover,
DAR5 exhibits immunoreactivity at apical and basolateral sides of
intestinal crypts, where its pharmacological stimulation promotes
epithelial K+ secretion via a cAMP-dependent mechanism, thus
ensuring the correct function of the intestinal mucosa (105).
Regarding the expression of DARs by immune cells, DAR5
expressed on DCs seems to favor the expression of both IL-12
and IL-23 in response to LPS, potentiating CD4+ T cell activation
(35). Considering the crucial role of IL-12 and IL-23 produced
by DCs in intestinal inflammation, it is possible that dopamine
acting via DAR5 on DCs may promote Th17 differentiation in the
gut and contribute to IBDs. Previous work showed that DAR3-
deficient CD4+ T cells mount impaired Th1 responses and fail to
induce neurodegeneration in a murine Parkinson’s disease model
(22). Taking into account the reduction in intestinal dopamine
levels [≈140 pg/ml in healthy individuals; ≈45 pg/ml in CD and
UC patients (95)] and the fact that DAR3 and DAR5 may be stim-
ulated at low dopamine concentrations, it is tempting to speculate
that low dopamine levels present in the inflamed gut may drive
an inflammatory phenotype in CD4+ T cells, thus perpetuating
chronic inflammation. Conversely, high dopamine concentrations
in the gut of healthy individuals would stimulate DAR2, promot-
ing the production of the anti-inflammatory cytokine IL-10 by
CD4+ T cells (42) and suppressing both increased motility and
ulcer development (102) (Table 1).
Taken together, the data discussed here support the hypothesis
that dopamine has an overall protective role in the intestinal envi-
ronment by acting over muscles and promoting the relaxation of
the gut and preventing ulcer and lesion development, which can
predispose individuals to develop intestinal inflammation. This
protective role is most probably lost during colitis onset, since
several lines of evidence indicate that dopamine levels decrease
upon intestinal inflammation; and under these conditions, low
dopamine levels may stimulate both the innate and adaptive com-
partments to produce highly inflammatory cytokines, favoring the
development of colitis. Exploration of this hypothesis could lead
to the development of novel therapies directed to dopaminergic
targets that may be useful in the control of intestinal inflammation
in IBD patients.
DOPAMINE AND SYNOVIAL INFLAMMATION IN
RHEUMATOID ARTHRITIS
The etiology of RA remains under investigation, but accumulating
evidence suggests that the disease develops in genetically predis-
posed individuals after exposure to environmental triggers. In
addition to the presence of autoantibodies such as rheumatoid fac-
tor and cytokines, there is an impaired expression of several B and
T lymphocyte subsets. Initial indications that dopamine signaling
Frontiers in Immunology | Inflammation March 2014 | Volume 5 | Article 117 | 10
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pacheco et al. Dopamine and autoimmunity
pathways are involved in the pathogenesis of RA come from the
negative association between schizophrenia, thought to be depen-
dent on excessive response of DAR2, and RA. Thus, in patients
with schizophrenia, the median incidence rate of RA approximates
0.09%, a rate that is only one-tenth of that seen in RA in the gen-
eral population (106). This negative association may suggest that
excessive stimulation of DAR2-like receptors by dopamine may
prevent the onset of RA.
In ex vivo studies, DAR1 was expressed at high levels in human
naive CD4+ T cells, and dopamine could increase the cAMP
concentrations in T cells via DAR1-like receptors, and subse-
quently induce the secretion of IL-4 and IL-5 (107). Addition-
ally, dopamine increases IL-6-dependent IL-17 secretion from
human T cells. Importantly, DAR1-like receptor antagonists
inhibit dopamine-mediated IL-6 and IL-17 secretion from human
T cells. This inhibitory effect by antagonizing DAR1-like receptors,
which was demonstrated with SCH-23390 and LE300 DAR1-like
receptor antagonists, involves the dopamine-mediated IL-6–Th17
axis (107).
Because dopamine is detectable in the inflamed synovial tissue
of RA patients (107), it was of interest to investigate the effects
of DAR-like receptor antagonists on RA development in animal
models. DBA/1 mice immunized with type II collagen develop
CIA, and treatment of the arthritic mice with the selective DAR1
antagonist SCH-23390 suppressed CIA severity (108). However,
the treatment did not affect serum levels of antibodies to type
II collagen or the Th1/Th17 differentiation of splenic T cells in
the treated animals. When bone marrow-derived macrophages
were stimulated in vitro in the presence of the DAR1 antagonist
SCH23390, alteration of inflammatory cytokine expression was
not observed, but their in vitro differentiation to osteoclasts was
inhibited. Importantly, co-administration of the selective DAR1
agonist A68930 abrogated the in vivo anti-arthritic effect and the
in vitro suppression of osteoclastogenesis by the DAR1 antagonist.
The results suggest that DAR1 blockade could represent a poten-
tially novel approach for RA treatment. Its effect could be partly
attributable to the inhibition of osteoclastogenesis. DCs could syn-
thesize and store dopamine, then release it to naive CD4+ T cells
upon DC–T cell interactions, and, thereby, affect helper T cell
differentiation. Such model is plausible because DCs have been
proposed to play a pivotal role in the initiation and perpetuation
of RA by presentation of arthritogenic antigens to T cells.
The effect of DAR-like receptor antagonists was also tested in
rheumatoid synovitis of SCID mice engrafted with human RA syn-
ovium (107). Macroscopically, remarkable retraction of synovial
tissue was observed in mice that received a DAR2-like receptor
antagonist. In contrast, vascular proliferation and tissue enlarge-
ment were observed in mice that received the DAR2-like recep-
tor antagonist. In the RA synovial/SCID mouse chimera model,
although the selective DAR2-like receptor antagonist haloperidol
significantly induced accumulation of IL-6+ and IL-17+ T cells,
and exacerbated cartilage destruction, SCH-23390 strongly sup-
pressed these responses. Taken together, the findings suggest that
dopamine released by DCs acts on the IL-6–Th17 axis and causes
aggravation of RA synovial inflammation.
During the last decade, the SNS has been proposed to be
involved in the pathogenesis of RA. In experimental studies, CIA
developed with less severity during early manifestations of dis-
ease in sympathectomized mice than in animals bearing intact
SNS (27), suggesting a pro-inflammatory role exerted by SNS.
In vivo, adoptive transfer of Tregs showed that an intact SNS
attenuates suppressive functions of Tregs during CIA, and results
in a significant increase of disease severity (27). In addition,
recent studies revealed that sympathetic nerve fibers are lost in
inflamed synovial tissue and, importantly, dopamine and NE
have been described to induce repulsion of sympathetic nerve
fibers (109). Of note, dopamine and NE are actively produced
by synovial TH+ leukocytes during RA, independently of SNS
function (110). Importantly, TH+ cells have been found in syn-
ovial tissue of RA patients, but not in healthy controls. Moreover,
those TH+ cells start to replace sympathetic nerve fibers around
the onset of disease, and modulation of locally produced cate-
cholamines has strong anti-inflammatory effects in vivo in CIA
and in vitro in samples obtained from synovial tissues of RA
patients (110). More recently, in vitro experiments have shown
that hypoxia stimulates expression of TH in synovial cells with a
consequent synthesis of catecholamines and inhibition of TNF-α
production in samples obtained from RA patients (111). Further-
more, the therapeutic relevance of these findings has been probed
in a mouse model wherein adoptive transfer of TH+ neuronal
cells generated from mouse mesenchymal stem cells into arthritic
mice decreased disease severity (111). When TH+ neuronal cells
were previously depleted of catecholamines by treatment with 6-
hydroxydopamine, the therapeutic effect in CIA was lost (111).
Thus, these data indicate that dopamine and other catecholamines
produced by leukocytes play an important regulatory role in the
physiopathology of RA.
In human naive CD4+ T cells, dopamine increases IL-6-
dependent IL-17 production via DAR-like receptors, in response
to anti-CD3 plus anti-CD28 antibodies. Furthermore, dopamine
localizes with DCs in the synovial tissue of RA patients and is sig-
nificantly increased in RA synovial fluid (107). Such observations,
together with the preclinical studies of dopamine receptor antago-
nists prompted studies in patients. This resulted in several clinical
trials that evaluated the effect of bromocriptine – a dopaminer-
gic agonist that exerts a therapeutic activity through action on
peripheral DARs – on RA disease activity. Clinical therapeutic
trials using 2.5–30 mg of bromocriptine per day in a single or
divided dose have shown efficacy with minimal side effects in the
treatment of rheumatic diseases (112). Bromocriptine administra-
tion induced immunosuppression of several immune parameters
and was associated with improvements in morning stiffness, grip
strength, numbers of swollen/painful joints, and the Health Assess-
ment Questionnaire disability index. Even though double-blind,
placebo-controlled studies are limited, the clinical observations
and trials support the use of bromocriptine, which is relatively
safe, as a non-standard primary or adjunctive therapy in the treat-
ment of recalcitrant RA, and associated conditions unresponsive
to traditional approaches.
Cabergoline is another potent dopamine receptor agonist of
DAR2 receptors. It exhibits a higher affinity for DAR2s; it also
has less severe side effects and more convenient dosing schedule
than bromocriptine. Its administration once or twice a week has
much less tendency to cause nausea than bromocriptine. A pilot
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randomized double-blind clinical trial carried out in 10 patients
with active RA reported improvement of tender and swollen
joints (113). In addition, patient assessment of pain and global
assessment of disease activity were significant when patients were
treated with the long-acting cabergoline, a drug whose potential
side-effects and cost are acceptable (Table 1).
LUPUS NEUROPSYCHIATRIC DYSFUNCTIONS AND THE
DOPAMINERGIC SYSTEM
Systemic lupus erythematosus is an autoimmune disease char-
acterized by the involvement of multiple organs, including the
kidneys and the brain. The disease course is variable and unpre-
dictable, and often difficult to treat. It is characterized by immune
deregulation and production of autoantibodies directed toward
a variety of nuclear antigens, such as chromatin, RNP, Ro, La,
Sm, Ku, and DNA. Despite considerable interest, the primary
disturbances that lead to the production of pathogenic autoan-
tibodies in SLE remain to be elucidated. It is, however, clear
that the disease is multifactorial, with genetic and environmen-
tal factors contributing to its pathogenesis (114, 115). Several
observations suggest that hormones are crucial regulators of SLE
activity, including its preponderance in women, the fluctuations of
disease activity with the menstrual cycle, the tendency of the dis-
ease to flare during pregnancy, and the remissions after menopause
or cyclophosphomide-induced ovarian failure (116).
Neurologic manifestations of unknown etiology are common
in SLE and have been proposed to represent a more severe form of
the disease, occurring in up to 75% of patients (117). They range
from diffuse CNS disorders, i.e., acute confusional state, psychosis,
anxiety, and depressive disorders, clinical to subclinical cognitive
disorders of variable functional significance, to CNS syndromes,
i.e., seizures, cerebrovascular disease, chorea and myelopathy,
transverse myelitis, demyelinating syndrome and aseptic menin-
gitis, headaches, and PNS disorders, i.e., polyneuropathies and
mononeuropathies, autonomic disorders, plexopathy, and myas-
thenia gravis. The neurologic manifestations may also include
Parkinsonian-like deficits and changes in the basal ganglia.
Although a pathologic neuro-immuno-endocrine circuitry has
not yet been elucidated, significant loss of central neurons seems to
underlie changes in sensorimotor function and behavior in many
SLE patients (117). Support for the notion that behavioral impair-
ments and neuronal demise are a consequence of autoimmu-
nity comes from several case studies in which cyclophosphamide
effectively reversed Parkinsonian-manifestations in SLE patients.
It is possible that disruption of the BBB and anti-neuronal
autoantibodies account for CNS manifestations of the disease.
Indeed, antibodies reacting with neuronal cell lines and brain
tissue have been reported in the sera and CSF of patients with
CNS-lupus, but they are also found in lupus patients with no clin-
ical evidence of CNS involvement. Yet, specific autoantibodies may
account for certain behavioral impairments (118). For example, a
single injection of anti-dopamine antibodies reduces motor activ-
ity in healthy mice. In parallel, autoantibodies targeting dopamin-
ergic neurons were associated with rapidly progressing Parkinson-
ian symptomatology in a SLE patient (119). Consistently, deposi-
tion of antigen–antibody complexes in choroidal blood vessels has
been associated with neuropsychiatric dysfunction.
Systemic lupus erythematosus is also frequently accompanied
by psychiatric manifestations of unknown origin. Although dam-
age of central neurons had been documented, little is known
about the neurotransmitter systems affected by the autoim-
mune/inflammatory process. Studies in lupus-prone MRL-lpr
mice point to imbalanced dopamine function and neurodegen-
eration in dopamine-rich brain regions (120). Reminiscent of
symptoms seen in patients, diseased MRL-lpr mice have impaired
coordination in a beam-walking task and neurological deficits,
and the accelerated autoimmune manifestations coincide with a
deviation in their behavioral performance from congenic controls.
The series of performance deficits in motivated behavior, emo-
tional reactivity, and learning/memory capacity in MRL-lpr mice
have been operationally defined as “autoimmunity-associated
behavioral syndrome” or AABS (121), and their physiopathology
has been the focus of investigation. Significant changes in brain
morphology have been observed at the onset of lupus-like dis-
ease in the MRL-lpr substrain, and post-mortem analysis revealed
impaired catabolism of neurotransmitters in brains of lupic mice.
Interestingly, autoimmune MRL-lpr mice exhibit behaviors rem-
iniscent of stressed animals in a number of performance tests.
The fact that the dopaminergic system of the mesencephalon
is important in the control of movements, emotion, and moti-
vated behavior, raises the issue of whether autoimmunity and
inflammation are associated with midbrain degeneration, and
whether anhedonic- and depressive-like behaviors may reflect an
outcome of autoimmunity-induced damage on the mesolimbic
dopaminergic system.
MRL-lpr brains show increased dopamine levels in the paraven-
tricular nucleus (PVN) and median eminence, decreased concen-
trations of serotonin in the PVN, enhanced levels of serotonin in
the hippocampus, and decreased NE levels in the prefrontal cortex
(121). Importantly, the behavioral deficits correlate with changes
in PVN and median eminence, suggesting that an imbalanced neu-
rotransmitter regulation of the hypothalamus–pituitary axis plays
a role in the etiology of behavioral dysfunctions induced by the
autoimmune disease in MRL-lpr mice.
The causative role of autoimmunity and inflammation in the
pathogenesis of AABS is supported by studies using the immuno-
suppressive drug cyclophosphamide, which prevents some behav-
ioral deficits in lupus animals (122). More specifically, this drug
prevents anxiety- and depressive-like behaviors as indicated by the
restoration of novel object exploration, increased responsiveness
to a sweet palatable solution, and reduced floating in the forced
swimming test (FST).
Deficits in neurotransmitter catabolism are known to often be a
consequence of aberrant synthesis and/or enzymatic activity, and
excessive levels of dopamine can be neurotoxic. Accumulation of
dopamine catabolism metabolites could contribute to the reduced
density of dopaminergic cells. Regarding experimental lupus, ele-
vated levels of dopamine in the brains of MRL-lpr mice and their
increased sensitivity to the dopamine receptor agonist quinpirole
are observations consistent with this notion (122).
There is now evidence that damage to central dopaminergic
circuits in MRL-lpr brains accounts for some behavioral deficits.
For example, chronic injection with the selective DAR2/DAR3
agonist quinpirole induced self-injurious behavior in lupus mice
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(121). Similarly, rotational behavior increased in MRL-lpr mice
following acute injection with the selective DAR2/DAR3 dopamine
agonist apomorphine. In the sucrose preference test, acute injec-
tion with the indirect dopamine agonist d-amphetamine failed
to alter the response rates of diseased animals to sucrose solu-
tions (120), while chronic treatment increased their mobility in
the FST. Immunosuppressive treatment, suppressing autoimmu-
nity and preventing hippocampal damage, circumvented an age-
related decline in spatial memory and retrieval. Taken together,
these results link neuropathological findings of dopaminergic cell
death in nigrostriatal, mesolimbic, and mesocortical pathways to
certain behavioral deficits (e.g., locomotor, motivated, and learn-
ing behaviors) in lupus-prone animals. Although the contribution
of peripheral disease manifestations to behavioral performance
cannot be excluded, these pharmacological results indicate that
anhedonic- and depressive-like behaviors are a consequence of
disease-driven damage to several dopamine systems in MRL-lpr
brains.
As discussed above, human lymphocytes express all subtypes
of DARs (DAR1–DAR5), each of which exerts specific actions on
the regulation of lymphocyte functions. Since there are indica-
tions that neuromediators are involved in SLE pathogenesis, it
was important to assess expression of dopamine receptor genes in
this disease. A study of a cohort of SLE patients by sybergreen-
based real-time PCR revealed that all receptors are expressed in
lupus PBMCs. In addition, DAR2 was underexpressed, and DAR4
was overexpressed, as compared to control individuals (123). Cell
sorting experiments of peripheral T and B lymphocytes disclosed
that the altered DAR2 and DAR4 expressions were borne by T
cells. These data support the view that these distorted expressions
of DAR2 and DAR4 play a role in the pathophysiology of SLE.
This assumption converges with the observation that lupus-prone
MRL-lpr mice exhibit increased dopamine levels in specific regions
of the brain, e.g., the PVN and median eminence (121).
It should be emphasized that changes in mRNA levels are often
not as pronounced as the resulting differences in protein amounts.
Therefore, comparison of the expression of DARs at the protein
level could reveal additional distortions in SLE patients and in
other lymphocytes subsets. A multicolor flow cytometric analysis
of these receptors with highly specific antibodies or fluorochrome-
labeled ligands and additional staining for different leukocyte
populations will represent a fast, accurate, and easy method to
assess DAR expression in blood samples. Such an approach would
allow easy screening of a high number of patients and testing if
the expression levels of DAR2 and DAR4 on T cells can be used as
a diagnostic marker.
The observed changes in DAR expression in lymphocytes could
influence immune functions in SLE patients through several
mechanisms. First, stimulation of DAR2 in T cells has been shown
to have functional consequences. Thus, DAR2 was found to be
effective in regulating the activation and differentiation of naive
CD4+ T cells by promoting polarization toward regulatory Treg
cells (4, 42, 44, 47). In SLE patients, Treg cell function and/or
numbers were reportedly diminished, which is consistent with the
observation that expression of the Treg cell-promoting DAR2 is
decreased in lupus (123). Second, DR4 is expressed in unstimu-
lated human T cells, and is effective in regulating the activation and
differentiation of naive CD4+ cells by triggering T cell quiescence
(4, 42, 44, 47). Its activation is associated with the expression of
KLF2, a transcription factor that regulates T cell quiescence (124)
and permits a functional link between the nervous system and T
cells. In SLE, there is an uncontrolled T cell proliferation that is
thought to play an important pathogenic role. Together with the
overexpression of DAR4 on lupus T cells (123), the observations
(44) suggest that inducing quiescence using specific DAR4 agonists
may represent a useful strategy in the treatment of this disease.
It has been hypothesized that the dopamine analog bromocrip-
tine has the potential to suppress autoimmune disease. This ratio-
nale was applied to the treatment of SLE and in its (NZB×NZW)
F1 mouse model. Treatment with bromocriptine was effective
in treating the autoimmune disease in this experimental model.
When treatment was started before the appearance of clini-
cal disease, bromocriptine could slow the course of SLE in
(NZB×NZW) F1 mice. In addition, this drug was effective in
treating established disease in this model (125). In another ani-
mal model of SLE, simultaneous treatment with estrogen and the
dopaminergic agent bromocriptine prevented the development of
a lupus-like syndrome in BALB/c mice that express a transgene
encoding a pathogenic anti-dsDNA antibody (126).
In clinical trials, bromocriptine showed evidence that it had a
therapeutic effect in treating human lupus. For example, treatment
with bromocriptine was found to be beneficial in SLE patients
with mild to moderately active disease, leading to decreased serum
immunoglobulin and anti-DNA antibody levels (112). Discontin-
uation of bromocriptine was followed by a flare of disease activity.
In another clinical trial, the therapeutic effect of bromocriptine
was found to be comparable to that of hydroxychloroquine, a
well-accepted treatment for cutaneous and articular manifesta-
tions of SLE (125). The fact that bromocriptine was effective in
treating (NZB×NZW) F1 mice, the beneficial therapeutic effects
in human trials, and the low toxicity of the drug represent a
solid rationale for undertaking further therapeutic trials. Thus,
these observations suggest that alterations in dopamine and/or
its receptors could be associated with the physiopathology of SLE
(Table 1).
CONCLUSIONS
Accumulating pharmacological and genetic evidence has indicated
a crucial role of dopamine in the regulation of inflammatory
responses involved in autoimmune disorders. Altered levels of
dopamine in inflamed tissues and deregulated expression of the
dopaminergic machinery in immune cells have been consistently
associated with the physiopathology of autoimmune diseases in
patients and in animal models, including MS, IBDs, SLE, and RA.
Accordingly, drugs targeting the dopaminergic machinery have
proven to be anti-inflammatory in vitro and in vivo in animal
models and, in some cases, also in human patients. Understanding
the precise mechanisms involving dopaminergic-mediated regu-
lation of the immune system and their alterations in autoimmune
disorders would allow development of drugs that could have ben-
eficial effects for the treatment of autoimmunity. Despite current
efforts in this field focusing in pharmacologically targeting com-
ponents of dopaminergic machinery as a therapeutic approach
in vivo in animal models of autoimmune diseases, there is a lack of
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available specific drugs, i.e., targeting DAR1 and DAR5. Therefore,
future efforts should focus on evaluation of the targeting potential
of these dopaminergic components in a receptor-specific manner
(for example, by developing new agonists/antagonists specific for
a particular receptor, or, alternatively, targeting specific receptor
expression, i.e., by inducing ectopic up- or down-regulation with
viral vectors). Furthermore, the complexity of dopaminergic reg-
ulation of the immune response, which involves several different
DARs expressed in diverse leukocyte types, suggests that future
therapies should point toward the development of strategies to
target specific DARs or enzymes in precise cell populations. In
this regard, recent studies have shown that adoptive transfer of
cells with an altered dopaminergic machinery may decrease dis-
ease severity in some animal models of autoimmunity. Finally, not
only targeting of neurotransmitter receptors should be assessed in
isolation as therapeutic approaches in immune-related diseases,
but also targeting different receptors in combination should be
considered.
ACKNOWLEDGMENTS
Moncef Zouali is supported by INSERM and University of Paris
Diderot, Sorbonne Paris Cité. Rodrigo Pacheco is supported
by grants FONDECYT-1130271 and PFB-16 from CONICYT,
and 2011-0001-R from Universidad San Sebastián. Francisco
Contreras holds a graduate fellowship 21100701 from CONICYT.
REFERENCES
1. Blalock JE. The syntax of immune-neuroendocrine communication. Immunol
Today (1994) 15:504–11. doi:10.1016/0167-5699(94)90205-4
2. Sarkar C, Basu B, Chakroborty D, Dasgupta PS, Basu S. The immunoregu-
latory role of dopamine: an update. Brain Behav Immun (2010) 24:525–8.
doi:10.1016/j.bbi.2009.10.015
3. McKenna F, McLaughlin PJ, Lewis BJ, Sibbring GC, Cummerson JA, Bowen-
Jones D, et al. Dopamine receptor expression on human T- and B-lymphocytes,
monocytes, neutrophils, eosinophils and NK cells: a flow cytometric study.
J Neuroimmunol (2002) 132:34–40. doi:10.1016/S0165-5728(02)00280-1
4. Pacheco R, Prado CE, Barrientos MJ, Bernales S. Role of dopamine in the
physiology of T-cells and dendritic cells. J Neuroimmunol (2009) 216:8–19.
doi:10.1016/j.jneuroim.2009.07.018
5. Pacheco R, Riquelme E, Kalergis AM. Emerging evidence for the role of neuro-
transmitters in the modulation of T cell responses to cognate ligands. Cent Nerv
Syst Agents Med Chem (2010) 10:65–83. doi:10.2174/187152410790780154
6. Prado C, Bernales S, Pacheco R. Modulation of T-cell mediated immunity
by dopamine receptor D5. Endocr Metab Immune Disord Drug Targets (2013)
13:184–94. doi:10.2174/1871530311313020007
7. Scheuermann DW. Comparative morphology, cytochemistry and innervation
of chromaffin tissue in vertebrates. J Anat (1993) 183(Pt 2):327–42.
8. Eisenhofer G, Aneman A, Friberg P, Hooper D, Fåndriks L, Lonroth H, et al.
Substantial production of dopamine in the human gastrointestinal tract. J Clin
Endocrinol Metab (1997) 82:3864–71. doi:10.1210/jc.82.11.3864
9. Vieira-Coelho MA, Soares-da-Silva P. Dopamine formation, from its immedi-
ate precursor 3,4-dihydroxyphenylalanine, along the rat digestive tract. Fun-
dam Clin Pharmacol (1993) 7:235–43. doi:10.1111/j.1472-8206.1993.tb00237.
x
10. Shechter R, London A, Schwartz M. Orchestrated leukocyte recruitment to
immune-privileged sites: absolute barriers versus educational gates. Nat Rev
Immunol (2013) 13:206–18. doi:10.1038/nri3391
11. Hatterer E, Touret M, Belin MF, Honnorat J, Nataf S. Cerebrospinal fluid den-
dritic cells infiltrate the brain parenchyma and target the cervical lymph nodes
under neuroinflammatory conditions. PLoS One (2008) 3:e3321. doi:10.1371/
journal.pone.0003321
12. Laman JD, Weller RO. Drainage of cells and soluble antigen from the
CNS to regional lymph nodes. J Neuroimmune Pharmacol (2013) 8:840–56.
doi:10.1007/s11481-013-9470-8
13. Anandasabapathy N, Victora GD, Meredith M, Feder R, Dong B, Kluger C,
et al. Flt3L controls the development of radiosensitive dendritic cells in the
meninges and choroid plexus of the steady-state mouse brain. J Exp Med (2011)
208:1695–705. doi:10.1084/jem.20102657
14. Yirmiya R, Goshen I. Immune modulation of learning, memory, neural plas-
ticity and neurogenesis. Brain Behav Immun (2011) 25:181–213. doi:10.1016/
j.bbi.2010.10.015
15. Derecki NC, Cardani AN, Yang CH, Quinnies KM, Crihfield A, Lynch KR, et al.
Regulation of learning and memory by meningeal immunity: a key role for
IL-4. J Exp Med (2010) 207:1067–80. doi:10.1084/jem.20091419
16. Radjavi A, Smirnov I, Kipnis J. Brain antigen-reactive CD4 T cells are sufficient
to support learning behavior in mice with limited T cell repertoire. Brain Behav
Immun (2013) 35:58–63. doi:10.1016/j.bbi.2013.08.013
17. Baruch K, Schwartz M. CNS-specific T cells shape brain function via the
choroid plexus. Brain Behav Immun (2013) 34:11–6. doi:10.1016/j.bbi.2013.
04.002
18. Lewitus GM, Schwartz M. Behavioral immunization: immunity to self-antigens
contributes to psychological stress resilience. Mol Psychiatry (2009) 14:532–6.
doi:10.1038/mp.2008.103
19. Lucin KM, Wyss-Coray T. Immune activation in brain aging and neurode-
generation: too much or too little? Neuron (2009) 64:110–22. doi:10.1016/j.
neuron.2009.08.039
20. Appel SH. CD4+ T cells mediate cytotoxicity in neurodegenerative diseases.
J Clin Invest (2009) 119:13–5. doi:10.1172/JCI38096
21. Brochard V, Combadière B, Prigent A, Laouar Y, Perrin A, Beray-Berthat V, et al.
Infiltration of CD4+ lymphocytes into the brain contributes to neurodegener-
ation in a mouse model of Parkinson disease. J Clin Invest (2009) 119:182–92.
doi:10.1172/JCI36470
22. González H, Contreras F, Prado C, Elgueta D, Franz D, Bernales S, et al.
Dopamine receptor D3 expressed on CD4+ T cells favors neurodegenera-
tion of dopaminergic neurons during Parkinson’s disease. J Immunol (2013)
190:5048–56. doi:10.4049/jimmunol.1203121
23. Reynolds AD, Stone DK, Hutter JA, Benner EJ, Mosley RL, Gendelman HE.
Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminer-
gic neurodegeneration in a model of Parkinson’s disease. J Immunol (2010)
184:2261–71. doi:10.4049/jimmunol.0901852
24. Barcia C, Ros CM, Annese V, Gómez A, Ros-Bernal F, Aguado-Llera D,
et al. IFN-gamma signaling, with the synergistic contribution of TNF-alpha,
mediates cell specific microglial and astroglial activation in experimental mod-
els of Parkinson’s disease. Cell Death Dis (2012) 3:e379. doi:10.1038/cddis.2012.
123
25. Henkel JS, Beers DR, Wen S, Rivera AL, Toennis KM, Appel JE, et al. Regulatory
T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival.
EMBO Mol Med (2013) 5:64–79. doi:10.1002/emmm.201201544
26. Mignini F, Tomassoni D, Traini E, Amenta F. Dopamine, vesicular transporters
and dopamine receptor expression and localization in rat thymus and spleen.
J Neuroimmunol (2009) 206:5–13. doi:10.1016/j.jneuroim.2008.09.018
27. Härle P,Pongratz G,Albrecht J,Tarner IH,Straub RH. An early sympathetic ner-
vous system influence exacerbates collagen-induced arthritis via CD4+CD25+
cells. Arthritis Rheum (2008) 58:2347–55. doi:10.1002/art.23628
28. Bhowmick S, Singh A, Flavell RA, Clark RB, O’Rourke J, Cone RE. The
sympathetic nervous system modulates CD4(+)FoxP3(+) regulatory T cells
via a TGF-beta-dependent mechanism. J Leukoc Biol (2009) 86:1275–83.
doi:10.1189/jlb.0209107
29. Grebe KM, Hickman HD, Irvine KR, Takeda K, Bennink JR, Yewdell JW. Sym-
pathetic nervous system control of anti-influenza CD8+ T cell responses. Proc
Natl Acad Sci U S A (2009) 106:5300–5. doi:10.1073/pnas.0808851106
30. Miura T, Kudo T, Matsuki A, Sekikawa K, Tagawa Y, Iwakura Y, et al. Effect of 6-
hydroxydopamine on host resistance against Listeria monocytogenes infection.
Infect Immun (2001) 69:7234–41. doi:10.1128/IAI.69.12.7234-7241.2001
31. Alaniz RC, Thomas SA, Perez-Melgosa M, Mueller K, Farr AG, Palmiter RD,
et al. Dopamine beta-hydroxylase deficiency impairs cellular immunity. Proc
Natl Acad Sci U S A (1999) 96:2274–8. doi:10.1073/pnas.96.5.2274
32. Franco R, Pacheco R, Lluis C, Ahern GP, O’Connell PJ. The emergence of
neurotransmitters as immune modulators. Trends Immunol (2007) 28:400–7.
doi:10.1016/j.it.2007.07.005
33. Cosentino M, Marino F, Bombelli R, Ferrari M, Rasini E, Lecchini S, et al. Stim-
ulation with phytohaemagglutinin induces the synthesis of catecholamines
in human peripheral blood mononuclear cells: role of protein kinase C and
Frontiers in Immunology | Inflammation March 2014 | Volume 5 | Article 117 | 14
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pacheco et al. Dopamine and autoimmunity
contribution of intracellular calcium. J Neuroimmunol (2002) 125:125–33.
doi:10.1016/S0165-5728(02)00019-X
34. Ferrari M, Cosentino M, Marino F, Bombelli R, Rasini E, Lecchini S, et al.
Dopaminergic D1-like receptor-dependent inhibition of tyrosine hydroxy-
lase mRNA expression and catecholamine production in human lymphocytes.
Biochem Pharmacol (2004) 67:865–73. doi:10.1016/j.bcp.2003.10.004
35. Prado C, Contreras F, González H, Díaz P, Elgueta D, Barrientos M, et al. Stimu-
lation of dopamine receptor D5 expressed on dendritic cells potentiates Th17-
mediated immunity. J Immunol (2012) 188:3062–70. doi:10.4049/jimmunol.
1103096
36. Nakano K, Higashi T, Takagi R, Hashimoto K, Tanaka Y, Matsushita S.
Dopamine released by dendritic cells polarizes Th2 differentiation. Int Immunol
(2009) 21:645–54. doi:10.1093/intimm/dxp033
37. Cosentino M, Fietta AM, Ferrari M, Rasini E, Bombelli R, Carcano E, et al.
Human CD4+CD25+ regulatory T cells selectively express tyrosine hydroxylase
and contain endogenous catecholamines subserving an autocrine/paracrine
inhibitory functional loop. Blood (2007) 109:632–42. doi:10.1182/blood-2006-
01-028423
38. Cosentino M, Zaffaroni M, Ferrari M, Marino F, Bombelli R, Rasini E, et al.
Interferon-gamma and interferon-beta affect endogenous catecholamines in
human peripheral blood mononuclear cells: implications for multiple sclero-
sis. J Neuroimmunol (2005) 162:112–21. doi:10.1016/j.jneuroim.2005.01.019
39. Beck GC, Brinkkoetter P, Hanusch C, Schulte J, van Ackern K, van derWoude
FJ, et al. Clinical review: immunomodulatory effects of dopamine in general
inflammation. Crit Care (2004) 8:485–91. doi:10.1186/cc2879
40. Cosentino M, Bombelli R, Ferrari M, Marino F, Rasini E, Maestroni GJ, et al.
HPLC-ED measurement of endogenous catecholamines in human immune
cells and hematopoietic cell lines. Life Sci (2000) 68:283–95. doi:10.1016/
S0024-3205(00)00937-1
41. Yong LC. The mast cell: origin, morphology, distribution, and function. Exp
Toxicol Pathol (1997) 49:409–24. doi:10.1016/S0940-2993(97)80129-7
42. Besser MJ, Ganor Y, Levite M. Dopamine by itself activates either D2, D3
or D1/D5 dopaminergic receptors in normal human T-cells and triggers the
selective secretion of either IL-10, TNFalpha or both. J Neuroimmunol (2005)
169:161–71. doi:10.1016/j.jneuroim.2005.07.013
43. Saha B, Mondal AC, Majumder J, Basu S, Dasgupta PS. Physiological con-
centrations of dopamine inhibit the proliferation and cytotoxicity of human
CD4+ and CD8+ T cells in vitro: a receptor-mediated mechanism. Neuroim-
munomodulation (2001) 9:23–33. doi:10.1159/000049004
44. Sarkar C, Das S, Chakroborty D, Chowdhury UR, Basu B, Dasgupta PS, et al.
Cutting Edge: Stimulation of dopamine D4 receptors induce T cell quies-
cence by up-regulating Kruppel-like factor-2 expression through inhibition
of ERK1/ERK2 phosphorylation. J Immunol (2006) 177:7525–9.
45. Watanabe Y, Nakayama T, Nagakubo D, Hieshima K, Jin Z, Katou F, et al.
Dopamine selectively induces migration and homing of naive CD8+ T cells via
dopamine receptor D3. J Immunol (2006) 176:848–56.
46. Kipnis J, Cardon M, Avidan H, Lewitus GM, Mordechay S, Rolls A,
et al. Dopamine, through the extracellular signal-regulated kinase pathway,
downregulates CD4+CD25+ regulatory T-cell activity: implications for neu-
rodegeneration. J Neurosci (2004) 24:6133–43. doi:10.1523/JNEUROSCI.
0600-04.2004
47. Ilani T, Strous RD, Fuchs S. Dopaminergic regulation of immune cells via D3
dopamine receptor: a pathway mediated by activated T cells. FASEB J (2004)
18:1600–2. doi:10.1096/fj.04-1652fje
48. Saha B, Mondal AC, Basu S, Dasgupta PS. Circulating dopamine level, in lung
carcinoma patients, inhibits proliferation and cytotoxicity of CD4+ and CD8+
T cells by D1 dopamine receptors: an in vitro analysis. Int Immunopharmacol
(2001) 1:1363–74. doi:10.1016/S1567-5769(01)00068-6
49. Sunahara RK, Guan HC, O’Dowd BF, Seeman P, Laurier LG, Ng G, et al.
Cloning of the gene for a human dopamine D5 receptor with higher affinity
for dopamine than D1. Nature (1991) 350:614–9. doi:10.1038/350614a0
50. Van Tol HH, Bunzow JR, Guan HC, Sunahara RK, Seeman P, Niznik HB,
et al. Cloning of the gene for a human dopamine D4 receptor with high
affinity for the antipsychotic clozapine. Nature (1991) 350:610–4. doi:10.1038/
350610a0
51. Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC. Molecular cloning
and characterization of a novel dopamine receptor (D3) as a target for neu-
roleptics. Nature (1990) 347:146–51. doi:10.1038/347146a0
52. Nakano K, Higashi T, Hashimoto K, Takagi R, Tanaka Y, Matsushita S. Antag-
onizing dopamine D1-like receptor inhibits Th17 cell differentiation: preven-
tive and therapeutic effects on experimental autoimmune encephalomyelitis.
Biochem Biophys Res Commun (2008) 373:286–91. doi:10.1016/j.bbrc.2008.06.
012
53. Chastain EM, Duncan DS, Rodgers JM, Miller SD. The role of antigen pre-
senting cells in multiple sclerosis. Biochim Biophys Acta (2011) 1812:265–74.
doi:10.1016/j.bbadis.2010.07.008
54. Jadidi-Niaragh F, Mirshafiey A. Histamine and histamine receptors in patho-
genesis and treatment of multiple sclerosis. Neuropharmacology (2010)
59:180–9. doi:10.1016/j.neuropharm.2010.05.005
55. Greter M, Heppner FL, Lemos MP, Odermatt BM, Goebels N, Laufer T, et al.
Dendritic cells permit immune invasion of the CNS in an animal model of
multiple sclerosis. Nat Med (2005) 11:328–34. doi:10.1038/nm1197
56. Tsai PJ, Huang PC. Circadian variations in plasma and erythrocyte con-
centrations of glutamate, glutamine, and alanine in men on a diet with-
out and with added monosodium glutamate. Metabolism (1999) 48:1455–60.
doi:10.1016/S0026-0495(99)90159-2
57. Bailey SL, Schreiner B, McMahon EJ, Miller SD. CNS myeloid DCs presenting
endogenous myelin peptides ‘preferentially’ polarize CD4+ T(H)-17 cells in
relapsing EAE. Nat Immunol (2007) 8:172–80. doi:10.1038/ni1430
58. Fletcher JM, Lalor SJ, Sweeney CM, Tubridy N, Mills KH. T cells in multiple
sclerosis and experimental autoimmune encephalomyelitis. Clin Exp Immunol
(2010) 162:1–11. doi:10.1111/j.1365-2249.2010.04143.x
59. Barr TA, Shen P, Brown S, Lampropoulou V, Roch T, Lawrie S, et al. B cell
depletion therapy ameliorates autoimmune disease through ablation of IL-6-
producing B cells. J Exp Med (2012) 209:1001–10. doi:10.1084/jem.20111675
60. Evdoshenko E, Maslyanskiy A, Lapin S, Zaslavsky L, Dobson R, Totolian A,
et al. Dynamics of B-cell populations in CSF and blood in patients treated
with a combination of rituximab and mitoxantrone. ISRN Neurol (2013)
2013:748127. doi:10.1155/2013/748127
61. Bałkowiec-Iskra E, Kurkowska-Jastrzebska I, Joniec I, Ciesielska A,
Członkowska A, Członkowski A. Dopamine, serotonin and noradrenaline
changes in the striatum of C57BL mice following myelin oligodendrocyte gly-
coprotein (MOG) 35-55 and complete Freund adjuvant (CFA) administration.
Acta Neurobiol Exp (Wars) (2007) 67:379–88.
62. Giorelli M, Livrea P, Trojano M. Dopamine fails to regulate activation of periph-
eral blood lymphocytes from multiple sclerosis patients: effects of IFN-beta.
J Interferon Cytokine Res (2005) 25:395–406. doi:10.1089/jir.2005.25.395
63. Zaffaroni M, Marino F, Bombelli R, Rasini E, Monti M, Ferrari M, et al.
Therapy with interferon-beta modulates endogenous catecholamines in lym-
phocytes of patients with multiple sclerosis. Exp Neurol (2008) 214:315–21.
doi:10.1016/j.expneurol.2008.08.015
64. Petermann F, Rothhammer V, Claussen MC, Haas JD, Blanco LR, Heink S,
et al. gammadelta T cells enhance autoimmunity by restraining regulatory T
cell responses via an interleukin-23-dependent mechanism. Immunity (2010)
33:351–63. doi:10.1016/j.immuni.2010.08.013
65. Codarri L, Gyülvészi G, Tosevski V, Hesske L, Fontana A, Magnenat L, et al.
RORgammat drives production of the cytokine GM-CSF in helper T cells,
which is essential for the effector phase of autoimmune neuroinflammation.
Nat Immunol (2011) 12:560–7. doi:10.1038/ni.2027
66. Cosentino M, Zaffaroni M, Trojano M, Giorelli M, Pica C, Rasini E, et al.
Dopaminergic modulation of CD4+CD25(high) regulatory T lymphocytes in
multiple sclerosis patients during interferon-beta therapy. Neuroimmunomod-
ulation (2012) 19:283–92. doi:10.1159/000336981
67. Lakatos PL. Recent trends in the epidemiology of inflammatory bowel diseases:
up or down? World J Gastroenterol (2006) 12:6102–8. doi:10.3748/wjg.v12.i38.
6102
68. Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, et al.
Increasing incidence and prevalence of the inflammatory bowel diseases
with time, based on systematic review. Gastroenterology (2012) 142:46.e–54.e.
doi:10.1053/j.gastro.2011.10.001 quiz e30,
69. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and
established and evolving therapies. Lancet (2007) 369:1641–57. doi:10.1016/
S0140-6736(07)60751-X
70. Brand S. Crohn’s disease: Th1, Th17 or both? The change of a paradigm: new
immunological and genetic insights implicate Th17 cells in the pathogenesis
of Crohn’s disease. Gut (2009) 58:1152–67. doi:10.1136/gut.2008.163667
www.frontiersin.org March 2014 | Volume 5 | Article 117 | 15
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pacheco et al. Dopamine and autoimmunity
71. Granlund Av, Flatberg A, Østvik AE, Drozdov I, Gustafsson BI, Kidd M, et al.
Whole genome gene expression meta-analysis of inflammatory bowel disease
colon mucosa demonstrates lack of major differences between Crohn’s disease
and ulcerative colitis. PLoS One (2013) 8:e56818. doi:10.1371/journal.pone.
0056818
72. Olsen T, Rismo R, Cui G, Goll R, Christiansen I, Florholmen J. TH1 and TH17
interactions in untreated inflamed mucosa of inflammatory bowel disease,
and their potential to mediate the inflammation. Cytokine (2011) 56:633–40.
doi:10.1016/j.cyto.2011.08.036
73. Kaser A, Zeissig S, Blumberg RS. Inflammatory bowel disease. Annu Rev
Immunol (2010) 28:573–621. doi:10.1146/annurev-immunol-030409-101225
74. Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune
responses during health and disease. Nat Rev Immunol (2009) 9:313–23.
doi:10.1038/nri2515
75. Kaser A, Blumberg RS. Endoplasmic reticulum stress in the intestinal epithe-
lium and inflammatory bowel disease. Semin Immunol (2009) 21:156–63.
doi:10.1016/j.smim.2009.01.001
76. Kamada N, Hisamatsu T, Okamoto S, Sato T, Matsuoka K, Arai K, et al. Abnor-
mally differentiated subsets of intestinal macrophage play a key role in Th1-
dominant chronic colitis through excess production of IL-12 and IL-23 in
response to bacteria. J Immunol (2005) 175:6900–8.
77. Abe K, Nguyen KP, Fine SD, Mo JH, Shen C, Shenouda S, et al. Conventional
dendritic cells regulate the outcome of colonic inflammation independently
of T cells. Proc Natl Acad Sci U S A (2007) 104:17022–7. doi:10.1073/pnas.
0708469104
78. Fort MM, Leach MW, Rennick DM. A role for NK cells as regulators of CD4+
T cells in a transfer model of colitis. J Immunol (1998) 161:3256–61.
79. Fujino S, Andoh A, Bamba S, Ogawa A, Hata K, Araki Y, et al. Increased expres-
sion of interleukin 17 in inflammatory bowel disease. Gut (2003) 52:65–70.
doi:10.1136/gut.52.1.65
80. Annunziato F, Cosmi L, Santarlasci V, Maggi L, Liotta F, Mazzinghi B, et al.
Phenotypic and functional features of human Th17 cells. J Exp Med (2007)
204:1849–61. doi:10.1084/jem.20070663
81. Powrie F, Mason D. OX-22high CD4+ T cells induce wasting disease with mul-
tiple organ pathology: prevention by the OX-22low subset. J Exp Med (1990)
172:1701–8. doi:10.1084/jem.172.6.1701
82. Rubtsov YP, Rasmussen JP, Chi EY, Fontenot J, Castelli L, Ye X, et al. Regulatory
T cell-derived interleukin-10 limits inflammation at environmental interfaces.
Immunity (2008) 28:546–58. doi:10.1016/j.immuni.2008.02.017
83. Maul J, Loddenkemper C, Mundt P, Berg E, Giese T, Stallmach A, et al. Periph-
eral and intestinal regulatory CD4+ CD25(high) T cells in inflammatory bowel
disease. Gastroenterology (2005) 128:1868–78. doi:10.1053/j.gastro.2005.03.
043
84. Saruta M, Yu QT, Fleshner PR, Mantel PY, Schmidt-Weber CB, Banham AH,
et al. Characterization of FOXP3+CD4+ regulatory T cells in Crohn’s disease.
Clin Immunol (2007) 125:281–90. doi:10.1016/j.clim.2007.08.003
85. Monteleone G, Boirivant M, Pallone F, MacDonald TT. TGF-beta1 and
Smad7 in the regulation of IBD. Mucosal Immunol (2008) 1(Suppl 1):S50–3.
doi:10.1038/mi.2008.55
86. Allez M, Brimnes J, Dotan I, Mayer L. Expansion of CD8+ T cells with regula-
tory function after interaction with intestinal epithelial cells. Gastroenterology
(2002) 123:1516–26. doi:10.1053/gast.2002.36588
87. Mizoguchi A, Bhan AK. A case for regulatory B cells. J Immunol (2006)
176:705–10.
88. Fuss IJ, Heller F, Boirivant M, Leon F, Yoshida M, Fichtner-Feigl S, et al.
Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an
atypical Th2 response in ulcerative colitis. J Clin Invest (2004) 113:1490–7.
doi:10.1172/JCI19836
89. Benarroch EE. Enteric nervous system: functional organization and neurologic
implications. Neurology (2007) 69:1953–7. doi:10.1212/01.wnl.0000281999.
56102.b5
90. Eaker EY, Bixler GB, Dunn AJ, Moreshead WV, Mathias JR. Dopamine and nor-
epinephrine in the gastrointestinal tract of mice and the effects of neurotoxins.
J Pharmacol Exp Ther (1988) 244:438–42.
91. Shichijo K, Sakurai-Yamashita Y, Sekine I, Taniyama K. Neuronal release of
endogenous dopamine from corpus of guinea pig stomach. Am J Physiol (1997)
273:G1044–50.
92. Mitsuma T, Rhue H, Hirooka Y, Kayama M, Wago T, Takagi J, et al. Distri-
bution of dopamine transporter in the rat: an immunohistochemical study.
Endocr Regul (1998) 32:71–5.
93. Singaram C, Ashraf W, Gaumnitz EA, Torbey C, Sengupta A, Pfeiffer R,
et al. Dopaminergic defect of enteric nervous system in Parkinson’s disease
patients with chronic constipation. Lancet (1995) 346:861–4. doi:10.1016/
S0140-6736(95)92707-7
94. Li ZS, Pham TD, Tamir H, Chen JJ, Gershon MD. Enteric dopaminergic neu-
rons: definition, developmental lineage, and effects of extrinsic denervation.
J Neurosci (2004) 24:1330–9. doi:10.1523/JNEUROSCI.3982-03.2004
95. Magro F, Vieira-Coelho MA, Fraga S, Serrão MP, Veloso FT, Ribeiro T, et al.
Impaired synthesis or cellular storage of norepinephrine, dopamine, and 5-
hydroxytryptamine in human inflammatory bowel disease. Dig Dis Sci (2002)
47:216–24. doi:10.1023/A:1013256629600
96. Magro F, Fraga S, Ribeiro T, Soares-da-Silva P. Decreased availability of intesti-
nal dopamine in transmural colitis may relate to inhibitory effects of interferon-
gamma upon L-DOPA uptake. Acta Physiol Scand (2004) 180:379–86. doi:10.
1111/j.1365-201X.2004.01260.x
97. Straub RH, Grum F, Strauch U, Capellino S, Bataille F, Bleich A, et al. Anti-
inflammatory role of sympathetic nerves in chronic intestinal inflammation.
Gut (2008) 57:911–21. doi:10.1136/gut.2007.125401
98. Rosas-Ballina M, Olofsson PS, Ochani M, Valdés-Ferrer SI, Levine YA, Reardon
C, et al. Acetylcholine-synthesizing T cells relay neural signals in a vagus nerve
circuit. Science (2011) 334:98–101. doi:10.1126/science.1209985
99. Matteoli G, Boeckxstaens GE. The vagal innervation of the gut and immune
homeostasis. Gut (2013) 62:1214–22. doi:10.1136/gutjnl-2012-302550
100. Hernandez DE, Adcock JW, Orlando RC, Patrick KS, Nemeroff CB, Prange AJ
Jr. Prevention of stress-induced gastric ulcers by dopamine agonists in the rat.
Life Sci (1984) 35:2453–8. doi:10.1016/0024-3205(84)90454-5
101. Sikiric P, Geber J, Suchanek E, Ivanovic D, Gjuris V, Aleksic J, et al. The role of
dopamine in the formation of gastric ulcers in rats. Eur J Pharmacol (1985)
112:127–8. doi:10.1016/0014-2999(85)90249-3
102. Miyazawa T, Matsumoto M, Kato S, Takeuchi K. Dopamine-induced protection
against indomethacin-evoked intestinal lesions in rats – role of anti-intestinal
motility mediated by D2 receptors. Med Sci Monit (2003) 9:BR71–7.
103. Magro F, Cunha E, Araujo F, Meireles E, Pereira P, Dinis-Ribeiro M, et al.
Dopamine D2 receptor polymorphisms in inflammatory bowel disease and
the refractory response to treatment. Dig Dis Sci (2006) 51:2039–44. doi:10.
1007/s10620-006-9168-3
104. Zhang X, Guo H, Xu J, Li Y, Li L, Zhang X, et al. Dopamine receptor D1 medi-
ates the inhibition of dopamine on the distal colonic motility. Transl Res (2012)
159:407–14. doi:10.1016/j.trsl.2012.01.002
105. Feng XY, Li Y, Li LS, Li XF, Zheng LF, Zhang XL, et al. Dopamine D1 receptors
mediate dopamine-induced duodenal epithelial ion transport in rats. Transl
Res (2013) 161:486–94. doi:10.1016/j.trsl.2012.12.002
106. Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, Kegeles LS, et al.
Increased baseline occupancy of D2 receptors by dopamine in schizophrenia.
Proc Natl Acad Sci U S A (2000) 97:8104–9. doi:10.1073/pnas.97.14.8104
107. Nakano K, Yamaoka K, Hanami K, Saito K, Sasaguri Y, Yanagihara N, et al.
Dopamine induces IL-6-dependent IL-17 production via D1-like receptor on
CD4 naive T cells and D1-like receptor antagonist SCH-23390 inhibits carti-
lage destruction in a human rheumatoid arthritis/SCID mouse chimera model.
J Immunol (2011) 186:3745–52. doi:10.4049/jimmunol.1002475
108. Nakashioya H, Nakano K, Watanabe N, Miyasaka N, Matsushita S, Kohsaka
H. Therapeutic effect of D1-like dopamine receptor antagonist on collagen-
induced arthritis of mice. Mod Rheumatol (2011) 21:260–6. doi:10.1007/
s10165-010-0387-2
109. Klatt S, Fassold A, Straub RH. Sympathetic nerve fiber repulsion: testing
norepinephrine, dopamine, and 17beta-estradiol in a primary murine sym-
pathetic neurite outgrowth assay. Ann N Y Acad Sci (2012) 1261:26–33.
doi:10.1111/j.1749-6632.2012.06628.x
110. Capellino S, Cosentino M, Wolff C, Schmidt M, Grifka J, Straub RH.
Catecholamine-producing cells in the synovial tissue during arthritis: modu-
lation of sympathetic neurotransmitters as new therapeutic target. Ann Rheum
Dis (2010) 69:1853–60. doi:10.1136/ard.2009.119701
111. Jenei-Lanzl Z, Capellino S, Kees F, Fleck M, Lowin T, Straub RH. Anti-
inflammatory effects of cell-based therapy with tyrosine hydroxylase-positive
Frontiers in Immunology | Inflammation March 2014 | Volume 5 | Article 117 | 16
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pacheco et al. Dopamine and autoimmunity
catecholaminergic cells in experimental arthritis. Ann Rheum Dis (2013).
doi:10.1136/annrheumdis-2013-203925
112. McMurray RW. Bromocriptine in rheumatic and autoimmune diseases. Semin
Arthritis Rheum (2001) 31:21–32. doi:10.1053/sarh.2001.25482
113. Mobini M, Kashi Z, Mohammad Pour AR, Adibi E. The effect of cabergoline
on clinical and laboratory findings in active rheumatoid arthritis. Iran Red
Crescent Med J (2011) 13:749–50. doi:10.5812/kowsar.20741804.2607
114. Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med (2008)
358:929–39. doi:10.1056/NEJMra071297
115. Zouali M. Epigenetics in lupus. Ann N Y Acad Sci (2011) 1217:154–65.
doi:10.1111/j.1749-6632.2010.05831.x
116. Karpuzoglu E, Zouali M. The multi-faceted influences of estrogen on lympho-
cytes: toward novel immuno-interventions strategies for autoimmunity man-
agement. Clin Rev Allergy Immunol (2011) 40:16–26. doi:10.1007/s12016-009-
8188-0
117. Muscal E, Brey RL. Neurologic manifestations of systemic lupus erythematosus
in children and adults. Neurol Clin (2010) 28:61–73. doi:10.1016/j.ncl.2009.09.
004
118. Diamond B, Volpe BT. A model for lupus brain disease. Immunol Rev (2012)
248:56–67. doi:10.1111/j.1600-065X.2012.01137.x
119. Kunas RC, McRae A, Kesselring J, Villiger PM. Antidopaminergic antibodies
in a patient with a complex autoimmune disorder and rapidly progressing
Parkinson’s disease. J Allergy Clin Immunol (1995) 96:688–90. doi:10.1016/
S0091-6749(95)70268-7
120. Anderson KK, Ballok DA, Prasad N, Szechtman H, Sakic B. Impaired response
to amphetamine and neuronal degeneration in the nucleus accumbens of
autoimmune MRL-lpr mice. Behav Brain Res (2006) 166:32–8. doi:10.1016/
j.bbr.2005.07.030
121. Sakic B, Lacosta S, Denburg JA, Szechtman H. Altered neurotransmission in
brains of autoimmune mice: pharmacological and neurochemical evidence.
J Neuroimmunol (2002) 129:84–96. doi:10.1016/S0165-5728(02)00171-6
122. Ballok DA, Earls AM, Krasnik C, Hoffman SA, Sakic B. Autoimmune-induced
damage of the midbrain dopaminergic system in lupus-prone mice. J Neuroim-
munol (2004) 152:83–97. doi:10.1016/j.jneuroim.2004.04.003
123. Jafari M, Ahangari G, Saberi M, Samangoui S, Torabi R, Zouali M. Dis-
torted expression of dopamine receptor genes in systemic lupus erythematosus.
Immunobiology (2013) 218:979–83. doi:10.1016/j.imbio.2012.11.002
124. Kuo CT, Veselits ML, Leiden JM. LKLF: a transcriptional regulator of single-
positive T cell quiescence and survival. Science (1997) 277:1986–90. doi:10.
1126/science.277.5334.1986
125. Walker SE. Bromocriptine treatment of systemic lupus erythematosus. Lupus
(2001) 10:762–8. doi:10.1191/096120301666625458
126. Peeva E, Grimaldi C, Spatz L, Diamond B. Bromocriptine restores tolerance in
estrogen-treated mice. J Clin Invest (2000) 106:1373–9. doi:10.1172/JCI10420
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 19 December 2013; paper pending published: 09 February 2014; accepted: 05
March 2014; published online: 21 March 2014.
Citation: Pacheco R, Contreras F and Zouali M (2014) The dopaminergic system in
autoimmune diseases. Front. Immunol. 5:117. doi: 10.3389/fimmu.2014.00117
This article was submitted to Inflammation, a section of the journal Frontiers in
Immunology.
Copyright © 2014 Pacheco, Contreras and Zouali. This is an open-access article dis-
tributed under the terms of the Creative Commons Attribution License (CC BY). The
use, distribution or reproduction in other forums is permitted, provided the original
author(s) or licensor are credited and that the original publication in this journal is cited,
in accordance with accepted academic practice. No use, distribution or reproduction is
permitted which does not comply with these terms.
www.frontiersin.org March 2014 | Volume 5 | Article 117 | 17
